Instructions for Authors

Scope
Cancer Epidemiology, Biomarkers & Prevention publishes original research on cancer causation and prevention in humans. The following topics are of special interest: descriptive, analytical, biochemical and molecular epidemiology; the use of biomarkers to study the neoplastic and preneoplastic processes in humans; chemoprevention and other types of prevention trials; and the role of behavioral factors in cancer etiology and prevention.

Particular attention will be given to the identification of factors associated with various aspects of the carcinogenic process, including genetic susceptibility, host factors, infectious agents, chemical and physical carcinogens, environmental contaminants, dietary components and behavioral factors such as sun exposure.

Besides welcoming manuscripts that address individual subjects in any of the three disciplines, the Editors encourage the submission of manuscripts with an interdisciplinary approach.

Contents
- Original research articles
- Invited editorials
- Selected review articles
- AACC and ASPO news

Editorial Policy
When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Furthermore, it is understood that all authors listed on a manuscript have agreed to its submission. Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the publisher and copyright owner of the journal, prior to publication. Once an article is accepted for publication in Cancer Epidemiology, Biomarkers & Prevention, the information therein is embargoed from reporting to the media until the mail date of the issue in which the article appears. The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. A copy of this declaration is available from the World Medical Association, Brotte Postale 63, 01212, Ferney-Voltaire Cedex, France.

Journal policy requires that authors, reviewers, and Associate Editors reveal to the Editor-in-Chief any relationships that they believe could be construed as causing a conflict of interest with regard to the manuscript submitted for review.

Manuscript Submission
Mail manuscripts to Cancer Epidemiology, Biomarkers & Prevention, AACR Publications Department, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Submit four original sets (not photocopies) of illustrations along with four copies of the manuscript. Illustrations will be returned to the author if the paper is not accepted for publication. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. FAX transmission and overnight delivery service will be used to expedite review and publication.

Publication Fees
A page charge of $50 per printed page will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see end of page for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Format
Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 × 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors, and affiliations;
2. A running title of fewer than 50 characters;
3. Text, arranged in this order: Abstract (not more than 250 words), Introduction, Materials and Methods, Results, Discussion, Acknowledgments, References;
4. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
5. Tables, on pages separate from the text, with descriptive titles and/or legends;
6. Figure legends, on pages separate from the text. Define all symbols and include staining for halftones, where applicable.

References
Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission.

Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

Sample references:

Illustrations
Provide four original sets of illustrations (whether line-cut drawings or halftones). Label each figure in pencil on the reverse side with the first author’s name, figure number, and an arrow indicating top of figure. Letters and numbers on illustrations should not be smaller than 6-point or larger than 12-point type. All illustrations will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with the greatest fidelity. Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. The cost of color reproduction charged to authors is $375 per color figure. Submit color illustrations on flexible backing.

Proofs
Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. Proofs not received by the deadline will be published without the authors’ corrections. Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive changes in proof.

Typesetting Manuscripts from Computer Disks
Cancer Epidemiology, Biomarkers & Prevention requests the submission of disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission and a form which must be completed and returned with your disk to the AACR Publications Department within 48 hours of notification of acceptance. It is the author’s responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

For More Information, Contact:
A New Resource Kit from the National Cancer Institute

- Cancer Research challenges, advances, and opportunities
- Cancer Statistics
- Research Initiatives
- Clinical Studies... and more

To order, call NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237)

A new resource kit from the National Cancer Institute focuses on cancer research challenges, advances, and opportunities. It includes information on cancer statistics, research initiatives, and clinical studies, along with contact information for the Cancer Information Service.

AMERICAN ASSOCIATION FOR CANCER RESEARCH

The American Association for Cancer Research (AACR) is a professional society of over 13,500 scientists and physicians involved in all aspects of basic, clinical, and translational cancer research. Members of the AACR enjoy

- subscriptions to Cancer Research, Cell Growth & Differentiation, Cancer Epidemiology, Biomarkers & Prevention, and Clinical Cancer Research at reduced member rates
- reduced registration rates at the AACR Annual Meeting, Special Conferences, and International Meetings
- Employment Register, Directory of Members, public education activities, and many other benefits

Special programs to provide enhanced career development opportunities for minority scientists include

- Session on Career Development at Annual Meeting
- Mentorship Program
- Travel Awards to Scientific Meetings

American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313

United States Postal Service
Statement of Ownership, Management, and Circulation
(Required by 39 USC 3689)

<table>
<thead>
<tr>
<th>Publication Title</th>
<th>Frequency</th>
<th>Copies Available</th>
<th>Copies Sold</th>
<th>Single Copy Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Epidemiology, Biomarkers &amp; Prevention</td>
<td>Biweekly</td>
<td>1,500</td>
<td>1,200</td>
<td>$110.00</td>
</tr>
</tbody>
</table>

1. Publication Title: Cancer Epidemiology, Biomarkers & Prevention
2. Issue Frequency: Biweekly
3. Copies Available: 1,500
4. Copies Sold: 1,200
5. Single Copy Price: $110.00

P.O. Box 2133, Department C, Philadelphia, PA 19105-3483


For questions or feedback, please contact the AACR at 1-800-4-CANCER (1-800-422-6237).
American Association for Cancer Research

90th Annual Meeting

April 10-14, 1999
Philadelphia, Pennsylvania

The World's Top Multidisciplinary Program
in The Cancer Field

Presenting The Most Up-To-Date Information in
Basic, Translational, and Clinical Cancer Research

In This Booklet:
• Abstract Submission Forms and Instructions
• Program Information
• Information on Awards for Basic, Translational, and Clinical Investigators
• Registration and Housing Information
• AACR Membership Application Forms
AMERICAN ASSOCIATION FOR CANCER RESEARCH
90TH ANNUAL MEETING

Pennsylvania Convention Center, Philadelphia, PA
April 10-14, 1999

Abstract Deadline: November 6, 1998

SPECIAL EVENTS
(Names with Confirmed Speakers/Organizers in Parentheses)

EDUCATIONAL SESSIONS AND METHODS WORKSHOPS
(SATURDAY AFTERNOON, APRIL 10, 1999)

To Be Announced

OFFICIAL OPENING EVENT
(SUNDAY MORNING, APRIL 11, 1999)

Presidential Address (Webster K. Cavenee)
Plenary Session: New Frontiers in Cancer Research (Wu Kang Hong)
Genetics (Robert A. Weinberg)
Immunology and Vaccine (Lloyd J. Old)
Therapeutics and Translation (Judah Folkman)
Hormonal Intervention and Prevention (C. Kent Osborne)
AACR-Peabody International Cancer Research Award Lecture
Special Lecture (James D. Watson)

SYMPOSIA

Drug Discovery: From afraid Science to the Clinic (Daniel D. Von Hoff)
Animal Models for Human Cancer: Recent Developments and New Challenges (Tyler Jacks)
Stem Cell Gene Therapy (Cynthia E. Dunbar)
Basic and Clinical Approaches to Lung Cancer (David P. Carbone)
Basic and Clinical Approaches to Ovarian Cancer (Robert C. Bast, Jr.)
Hormonally Related Tumors - Basic and Clinical Aspects (Bert W. O'Malley and Marc E. Lippman)
Dendritic Cell Vaccines (Ronald Levy)
Topoisomerase in Carcinogenesis and Cancer Treatment (Leroy F. Lin)
Infectious Agents and Cancer (Nancy E. Mueller)
Advances in Chemoprevention (Raymond N. DuBois)
Diet and Cancer (John D. Potter)
Signal Transduction (Geoffrey M. Wahl)
Genomics, Genetics, and New Approaches to Cancer (Richard D. Klausner)
Confronting the Tobacco Epidemic (Virginia L. Emrster)
Apoptosis (Craig B. Thompson)
Telomeres, Centromeres, and Chromosomal Instability (Carol W. Greider)
Genetic Instability, DNA Damage, and Checkpoint Regulation (Edward M. Wehr)
Invasion, Metastasis, and Angiogenesis (Isaac J. Fidler)
DNA Repair
Ubiquitin and Protein Degradation (Alexander Varahavsky)
Gene-Environment and Gene-Gene Interactions (Kenneth Olden and Margaret R. Pinta)
Replication and the Cell Cycle (Jacqueline A. Lee)
Transcriptional Regulation and Cancer (Stakins J. Gudas)
Drug Resistance and Cell Cycle Gene Abnormalities (Joseph R. Berlino)
Late-Breaking News (Speakers To Be Selected Shortly Before the Meeting)

"MEET-THE-EXPERT" SUNRISE SESSIONS

Drug Resistance (Susan P. Cole)
Molecular Detection of Minimal Residual Disease (Theodore F. Zipf)
Cancer Screening (Barry S. Kramer)
Microsatellite Instability
Design of Chemoprevention Trials (David S. Alberts)
Genetic Imprinting
Molecular Signaling of CML (Jean Y. Wang)
Cancer Metastasis: Cellular and Clinical Studies (David Tarin)
Embryonal Stem-Cell-based Technology (Randall S. Johnson)
bcl-2: Its Family and Modification (Timothy J. McDonnell)
Apoptosis and Chemotherapy (John A. Hickman)
Caspases
Replicative Senescence (Judith Campisi)
DNA Damage and Checkpoint Control
Nutritional Agents and Treatment (Leroy F. Liu)
Drug Targets (Peter J. Kavanagh)
Small Molecule Therapeutics
Molecular Processes in DNA Repair (Bruce A. J. Ponder)
Differentiation Therapy (Samuel Waxman)
New Therapeutic Agents
AIDS-related Malignancies (Ellen Peigal)
Molecular Genetics of Colon Cancer
Behavioral Oncology (Barbara K. Rimer)
Mdm2 (Guillermina Lozano)
Origins of Melanoma (Margaret A. Tucker)
Natural Agents and Chemoprevention (Hirotaka Fujiki)
Tumor Vaccine Therapy (Michael T. Lotze)
Genetics of Wilms Tumor (Michael R. DeBauf)
Biogenesis of Premalignant Lesions (Walter N. Hittelma)
Prospects for Biological Agents (Peter J. Houghton)
Antibodies as Chemotherapeutic Agents
Antisense Therapies (Stanley T. Crooke)
EGF Receptor Blockade (John Mendelsohn)

FORUMS

Tamoxifen: Risks and Benefits
Ethical and Legal Issues in Genetic Testing

Further Information: AACR Office • Public Ledger Building, Suite 826 •
150 S. Independence Mall West • Philadelphia, PA 19106-3483 •
Telephone: 215-440-9300 • FAX: 215-440-9313 •
E-mail: meetings@aacr.org • Website: http://www.aacr.org
TABLE OF CONTENTS

TOPICS OF SPECIAL SESSIONS
AT 1999 ANNUAL MEETING

LETTER FROM THE PROGRAM CHAIRPERSON,
WAUN KI HONG

1999 AACR ANNUAL MEETING
TENTATIVE SCHEDULE OF EVENTS

GENERAL INFORMATION

REGULATIONS APPLYING TO
ABSTRACTS AND PROFFERED PAPERS

INSTRUCTIONS FOR THE PREPARATION
AND MAILING OF ABSTRACTS

ABSTRACT CATEGORY/SUBCLASSIFICATION LIST

COPYRIGHT TRANSFER/CONFLICT OF
INTEREST DISCLOSURE FORM

SAMPLE COMPLETED ABSTRACT

OFFICIAL ABSTRACT FORMS

MEMBERSHIP APPLICATION FORMS

Active and Corresponding

Associate

HOUSING INFORMATION

TRAVEL AWARDS AVAILABLE

FORTHCOMING AACR SCIENTIFIC CONFERENCES

ADVANCE REGISTRATION

Frequently Asked Questions

Registration Form

ANNUAL MEETING PROGRAM
COMMITTEE MEMBERS

Be sure to fill out and return the acknowledgment
card included with these instructions.
Dear Colleague:

We are very excited about the upcoming 1999 Annual Meeting Program and believe that once you have reviewed this Call for Abstracts, you will share our excitement. For the last five months I have been working along with the Program Committee Co-Chairpersons (Joe Fraumeni, Carol Greider, and Leroy Liu) and other members of the Committee to survey the entire field of cancer research and to identify both today's most rapidly developing research areas and the most appropriate scientists to organize the sessions in which these new data will be presented. We have made special efforts to ensure that the Program properly reflects the exciting progress in translational research that is taking place in many areas of the cancer field. A great deal of work still needs to be done on the Program, especially the review and scheduling of the important abstracts you will submit. However, if the progress made to date is any indication, the meeting in Philadelphia will be an outstanding one. We would like to highlight below some of the important features of the meeting and draw your attention to some of the important information in this booklet.

Symposia and “Meet-the-Expert” Sunrise Sessions. The list of special sessions on the inside front cover of this booklet shows the considerable progress we have already made on the major symposia and the “meet-the-expert” sunrise sessions to take place this April. We anticipate that all cancer researchers, regardless of their scientific specialties, will find a good number of these sessions of intense interest. Of course, this list becomes more complete almost daily as more scientists accept our invitations to organize these sessions. Please consult the Association’s Website (http://www.aacr.org) for regular updates. We are very grateful to the nearly 50 Chairpersons of the various subcommittees of the Program Committee who made the initial suggestions from which the lists of symposia and sunrise sessions were developed. Clearly, without their insights and timely responses to our memoranda and questionnaires, the 1999 Program would not have been as comprehensive or exciting.

Opening Event. We would like to draw your particular attention to the Opening Event, "New Frontiers in Cancer Research," on Sunday morning, April 11. After Web Cavenee’s Presidential Address, four outstanding scientists (Robert A. Weinberg, Lloyd J. Old, Judah Folkman, and C. Kent Osborne) will give overviews of the most important developments in their respective fields. This plenary session will be followed by the 1999 AACR-Pezcoller International Cancer Research Award Lecture and then finally by a new feature of the annual meeting, an inspiring Nobel Laureate Lecture. We are very pleased to announce that James D. Watson has agreed to present this talk.

Submission of Abstracts. The principal goal of this booklet is to give you the information you need to submit an abstract of your work for presentation at the meeting. We urge you to do so because your participation is essential to the meeting’s goal of presenting all of the latest research findings in all of the subdisciplines of cancer research. The abstract categories and subclassifications were reorganized last year to reflect new advances in the field. These should make it easier for you to categorize your work and ensure that it is reviewed by the most appropriate members of the Program Committee. Please review this list (Pages 10-12) and then carefully follow the instructions on Pages 5-9 as you prepare and submit your abstract.

Late-Breaking Sessions. Another innovation this year is the addition of a second session of late-breaking papers, one which consists of invited presentations. As the pace of scientific discovery accelerates, it is essential that we develop new procedures to ensure that our meeting presents the most up-to-date and novel information. This Fall and Winter, Web Cavenee, the Program Committee Co-Chairpersons (Joe Fraumeni, Carol Greider, and Leroy Liu), and I will be closely monitoring scientific developments and will then ask scientists doing particularly important new work to make presentations in a special symposium which Web and I will chair on Wednesday, April 14. The meeting will still feature the session of proffered late-breaking papers that has become so popular since its inception in 1995. As you know, the latter session consists of important work completed after the abstract deadline of November 6, 1998; this event will take place late on Tuesday morning, April 13. If enough high-quality abstracts are received by this year’s deadline (March 12, 1999), this session will again consist of both oral and poster presentations.

You can contribute to the success of both of these sessions. If you are aware of particularly exciting new work that would be appropriate for the late-breaking symposium of invited speakers, please let us know about it. We anticipate issuing invitations to these speakers around January 15, 1999. Also, if you yourself make an important discovery after the November 6, 1998, deadline, be sure to submit an abstract for the late-breaking session of proffered papers by March 12.

Registration/Housing. Both the Local Arrangements Committee, which Bob Ozols is chairing, and the AACR Staff are looking forward to welcoming you to their home city. For the first time the AACR is offering a discounted, "early bird" registration rate (deadline of December 1, 1998). Many scientists make their decisions to attend the annual meeting well in advance, and we want to reward this loyalty with our new registration feature. See Page 31 for details.

Registrants may make hotel reservations via telephone, FAX, or the Internet. Complete instructions and information about participating hotels can be found on Pages 23-28. As we anticipate an even larger attendance than last year, the AACR has reserved over 1,000 more hotel rooms for the Philadelphia meeting than were reserved in New Orleans. About 3,000 of these rooms are within a 10-block radius of the Pennsylvania Convention Center (the site of scientific sessions), and all of them are less than a 30-minute drive from the Center. Complimentary shuttle buses will be provided between the Center and all meeting hotels except the Philadelphia Marriott, the Association’s headquarters hotel. (The Marriott is connected to the Center.) You will see from the information provided that the majority of the hotels outside the vicinity of the Center are located at the Philadelphia airport for convenient arrivals and departures.

Summary. We hope you will consider this booklet to be your invitation to submit an abstract, register for the meeting, obtain a hotel room, and attend the 90th Annual Meeting of the AACR this April. If you are not already a member of the Association, please also consider submitting an application at this time so that you can enjoy all of the benefits of membership, including significantly reduced registration rates for this and other AACR scientific meetings. Established scientists will find the application for active or corresponding membership on Pages 19-20. The next deadline for submission is January 1, 1999. Graduate and medical students, postdoctoral fellows, and physicians in training will find the associate member application on Pages 21-22. Please note that these applications may be submitted at any time but must be received by February 15, 1999, to qualify for reduced registration rates.

With your participation the AACR Annual Meeting will continue to be the world’s most important venue for the presentation of high-quality basic, translational, and clinical cancer research, the meeting that no cancer researcher can afford to miss. We look forward to seeing you in Philadelphia.

Very truly yours,

[Signature]

Wan Ki Hong, M.D.
1999 Program Committee Chairperson
# 1999 AACR Annual Meeting Schedule of Events

**SATURDAY, APRIL 10**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.-2:00 p.m.</td>
<td>Associate Member Grant-writing Session</td>
</tr>
<tr>
<td>9:30 a.m.-12:00 noon</td>
<td>Public Forum</td>
</tr>
<tr>
<td>12:00 noon-2:00 p.m.</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>2:00-6:00 p.m.</td>
<td>Methods Workshops</td>
</tr>
<tr>
<td>2:15-4:15 p.m.</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>4:30-6:30 p.m.</td>
<td>Educational Sessions</td>
</tr>
<tr>
<td>6:30-8:30 p.m.</td>
<td>WICR Guest Lecture and Reception</td>
</tr>
<tr>
<td>8:00-10:00 p.m.</td>
<td>Opening Mixer</td>
</tr>
</tbody>
</table>

**SUNDAY, APRIL 11**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-8:00 a.m.</td>
<td>Meet-the-Expert Sunrise Sessions</td>
</tr>
<tr>
<td>7:00-8:00 a.m.</td>
<td>NIH Grants Session</td>
</tr>
<tr>
<td>8:00 a.m.-12:00 noon</td>
<td>Poster Sessions</td>
</tr>
<tr>
<td>8:00-9:00 a.m.</td>
<td>Presidential Address and Elion Award and Fellowships Presentations</td>
</tr>
<tr>
<td>9:00 a.m.-11:00 a.m.</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>11:00 a.m.-12:00 noon</td>
<td>AACR-Pezcoller Award Lecture</td>
</tr>
<tr>
<td>12:00 noon-1:00 p.m.</td>
<td>Nobel Laureate Lecture</td>
</tr>
<tr>
<td>12:00 noon-5:00 p.m.</td>
<td>Exhibit Open</td>
</tr>
<tr>
<td>1:15-5:15 p.m.</td>
<td>Poster and Poster Discussion Sessions</td>
</tr>
<tr>
<td>1:15-2:15 p.m.</td>
<td>Associate Member Business Meeting</td>
</tr>
<tr>
<td>1:30-5:00 p.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>2:15-4:45 p.m.</td>
<td>Symposium</td>
</tr>
<tr>
<td>5:00-6:00 p.m.</td>
<td>Clowes Award Lecture</td>
</tr>
<tr>
<td>6:30-8:30 p.m.</td>
<td>Minority Issues Committee Careers Symposium</td>
</tr>
<tr>
<td>9:00-11:30 p.m.</td>
<td>Annual Reception</td>
</tr>
</tbody>
</table>

**MONDAY, APRIL 12**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-8:00 a.m.</td>
<td>Meet-the-Expert Sunrise Sessions</td>
</tr>
<tr>
<td>7:00-8:00 a.m.</td>
<td>WICR Mentoring Session</td>
</tr>
<tr>
<td>8:00-10:30 a.m.</td>
<td>Symposium</td>
</tr>
<tr>
<td>8:00 a.m.-12:00 noon</td>
<td>Poster and Poster Discussion Sessions</td>
</tr>
<tr>
<td>8:15-11:45 a.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>10:00 a.m.-4:00 p.m.</td>
<td>Exhibit Show Open</td>
</tr>
<tr>
<td>10:45 a.m.-12:00 noon</td>
<td>Controversy Session</td>
</tr>
<tr>
<td>12:00 noon-1:00 p.m.</td>
<td>Burchenal Award Lecture</td>
</tr>
</tbody>
</table>

**MONDAY, APRIL 12 (CONT.)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00-2:15 p.m.</td>
<td>NCI Board of Scientific Advisors Session</td>
</tr>
<tr>
<td>1:00-5:00 p.m.</td>
<td>Poster and Poster Discussion Sessions</td>
</tr>
<tr>
<td>1:15-2:15 p.m.</td>
<td>American Cancer Society Lecture</td>
</tr>
<tr>
<td>1:30-5:00 p.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>2:30-5:00 p.m.</td>
<td>Symposia</td>
</tr>
<tr>
<td>5:15-6:15 p.m.</td>
<td>Rhoads Award Lecture</td>
</tr>
<tr>
<td>6:30-8:30 p.m.</td>
<td>WICR Business Meeting</td>
</tr>
<tr>
<td>7:00-8:30 p.m.</td>
<td>NCI Training Branch Workshop</td>
</tr>
</tbody>
</table>

**TUESDAY, APRIL 13**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-8:00 a.m.</td>
<td>Meet-the-Expert Sunrise Sessions</td>
</tr>
<tr>
<td>7:00-8:00 a.m.</td>
<td>Associate Member Sunrise Session</td>
</tr>
<tr>
<td>8:00-10:30 a.m.</td>
<td>Symposium</td>
</tr>
<tr>
<td>8:00 a.m.-12:00 noon</td>
<td>Poster and Poster Discussion Sessions</td>
</tr>
<tr>
<td>8:15-11:45 a.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>10:00 a.m.-4:00 p.m.</td>
<td>Exhibit Show Open</td>
</tr>
<tr>
<td>10:30 a.m.-12:00 noon</td>
<td>Late-Breaking Research Session (proffered papers)</td>
</tr>
<tr>
<td>12:15-1:15 p.m.</td>
<td>Business Meeting of Members</td>
</tr>
<tr>
<td>1:15-5:15 p.m.</td>
<td>Poster and Poster Discussion Sessions</td>
</tr>
<tr>
<td>1:30-2:30 p.m.</td>
<td>Rosenthal Award Lecture</td>
</tr>
<tr>
<td>1:30-5:00 p.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>2:45-5:15 p.m.</td>
<td>Symposia</td>
</tr>
<tr>
<td>5:15-6:15 p.m.</td>
<td>Cain Award Lecture</td>
</tr>
</tbody>
</table>

**WEDNESDAY, APRIL 14**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-8:00 a.m.</td>
<td>Meet-the-Expert Sunrise Sessions</td>
</tr>
<tr>
<td>7:30-11:30 a.m.</td>
<td>Poster Discussion Sessions</td>
</tr>
<tr>
<td>8:00-10:30 a.m.</td>
<td>Late-Breaking Research Symposium</td>
</tr>
<tr>
<td>8:00 a.m.-12:00 noon</td>
<td>Poster Sessions</td>
</tr>
<tr>
<td>8:15-11:45 a.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>9:00 a.m.-12:00 noon</td>
<td>Exhibit Show Open</td>
</tr>
<tr>
<td>10:45-11:30 a.m.</td>
<td>Goodman Lecture</td>
</tr>
<tr>
<td>10:45 a.m.-12:00 noon</td>
<td>Controversy Session</td>
</tr>
<tr>
<td>12:00 noon-4:00 p.m.</td>
<td>Poster Discussion Sessions</td>
</tr>
<tr>
<td>12:15-3:45 p.m.</td>
<td>Minisymposia</td>
</tr>
<tr>
<td>12:30-3:00 p.m.</td>
<td>Symposia</td>
</tr>
</tbody>
</table>
PUBLICATION OF THE CALL FOR ABSTRACTS

This Call for Abstracts appears in a booklet that was mailed in September 1998 to all AACC members and to nonmembers who have expressed an interest in AACR meetings in the past. It is also published in the September 15, October 1, and October 15 issues of Cancer Research and in the October issues of Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention.

Additional copies are available from the Meetings Department in the AACR Office at 215-440-9300 (Telephone), 215-440-9313 (FAX), and meetings@aacr.org (E-mail).

HOW TO REGISTER

The advance registration form appears on Page 32, and important details about the registration process appear on Page 31. Please note the following important deadlines:

December 1, 1998: New, Reduced Rate "Early Bird" Registration
February 1, 1999: Advance Registration to Ensure Receipt of Meeting Publications in March
February 22, 1999: All Registration by Mail
March 26, 1999: Cancellation of Advance Registration to Receive Refund (less administrative fee)

On-Site registration will be possible at the Pennsylvania Convention Center from April 10-14, 1999.

SCIENTIFIC PROGRAM

Details of the 1999 Program that are currently available appear on the inside front cover of this booklet. A tentative schedule of events appears on Page 3. Regular updates will be posted on the Association’s Website (http://www.aacr.org).

ANNUAL MEETING PUBLICATIONS

The Annual Meeting Program contains the authors, titles, times, and locations of all presentations at the annual meeting. The Proceedings of the American Association for Cancer Research contains the abstracts of all published papers accepted for presentation at the annual meeting. All active, corresponding, and associate members of the AACR who have paid their dues for 1999 receive the Program and Proceedings as part of their dues payments. Nonmember and postdoctoral student registrants receive the Program, and nonmember registrants also receive the Proceedings as part of their registration fees. Additional copies of the Proceedings may be purchased at a cost of $35 for members and $45 for nonmembers.

The Association will mail only badges and receipts to overseas advance registrants who do not pay the postage surcharge described on the advance registration form. If you register in advance and do not receive your publication(s) before you depart for the meeting, please bring your receipt with you to the Issue Pickup Booth in the Registration Area at the Pennsylvania Convention Center. Show your receipt at the Booth to receive the appropriate publication(s).

ELECTRONIC PUBLICATION OF AACC PROGRAM AND PROCEEDINGS

An electronic version of the AACC Program and Proceedings will be available at the AACR’s Website in March 1999. It will be possible to search the full text of abstracts of papers being presented for key words and to develop a personal schedule of sessions of interest.

SUPPORT FOR ATTENDANCE

See Page 7 of this booklet for details about the following awards for qualified participants in the annual meeting:

Travel Awards for Young Investigators Who Are Authors of Outstanding Abstracts: These awards are given to graduate and medical students, postdoctoral fellows, and physicians in training who, in the opinion of the Program Committee, have submitted outstanding abstracts. No separate application form is necessary. Qualified persons who check box 5A on the abstract form and submit the abstract by the November 6, 1998, deadline are automatically considered.

AACR Minority Scholar Awards. Using funds from the Comprehensive Minority Biomedical Program of the NCI, the AACR supports the annual meeting participation of graduate and medical students, postdoctoral fellows, and physicians in training who are members of the following minority groups defined by the NCI as underrepresented in cancer research: African American, Hispanic American, Native American, Alaskan Native, and Native Pacific Islander. Interested candidates should request an application form from the AACR Minority Scholar Award Coordinator at 215-440-9300 (Telephone), 215-440-9412 (FAX), and felder@aacr.org (E-mail). This form must be completed and returned by December 4, 1998.

AACR-HBCU Faculty Award in Cancer Research. The AACR has received a grant from the Comprehensive Minority Biomedical Program of the NCI to support participation in the annual meeting by faculty members at Historically Black Colleges and Universities (HBCU). Applicants must have full-time appointments at the level of Assistant Professor or above and be engaged in meritorious basic, clinical, or translational cancer research at an HBCU. Information and application forms are available from the AACR’s HBCU Award Coordinator at 215-440-9300 (Telephone), 215-440-9412 (FAX), and felder@aacr.org (E-mail). The deadline for receipt of applications in the AACR Office will be December 4, 1998.

HOTEL RESERVATIONS

Please read the instructions for making hotel reservations on Page 23 of this booklet and then make your reservation by telephone, FAX, or Internet. From Saturday, April 10, through Wednesday, April 14, shuttle bus service will be provided between the Pennsylvania Convention Center and hotels assigned to AACR registrants according to schedules to be posted in the Center and in the hotels. There will be no shuttle bus service to the Philadelphia Marriott Hotel, the Association’s Headquarters Hotel, because it is connected to the Convention Center.

CHILD CARE

The AACR will once again provide professional child care services for infants and children ages 6 months to 11 years of age during the annual meeting. Exact hours and costs of this service will be published in January 1999.

COMMERCIAL EXHIBITS

The 1999 AACC Exhibit Show will be the largest in the Association’s history. It will gather together an anticipated 300 companies with the latest products and services for laboratory and clinical research. Exhibit booths will be located in Exhibit Hall B adjacent to the poster sessions. Show hours are as follows:

Sunday, April 11: 12:00 noon to 5:00 p.m.
Monday, April 12: 10:00 a.m. to 4:00 p.m.
Tuesday, April 13: 10:00 a.m. to 4:00 p.m.
Wednesday, April 14: 9:00 a.m. to 12:00 noon

Complimentary coffee, tea, and soft drinks will be served in the Exhibit Area at specified times on each day that exhibits are open. See the final Program for details.

Please visit the exhibits during the meeting as the firms involved are making a significant contribution to the educational value of the meeting and to the Association’s financial stability. If your firm needs an application form for exhibit space, please contact:

Ms. Susan Capper AACR Exhibit Manager • Slack Incorporated 6900 Grove Road • Thorofare, NJ 08086 609-848-1000

EMPLOYMENT REGISTER

The AACR will operate an Employment Register in the Convention Center during the 1999 Annual Meeting and will schedule interviews for registered employers and candidates. Instructions and forms for participation in the employment register are available from the AACR Office. Registration will also be possible at the meeting. Candidate and position listings received in the AACR Office by December 7, 1998, will be published in the Proceedings.

SPACE FOR SPECIAL FUNCTIONS

The AACR will entertain requests for space for special functions or receptions in the Philadelphia Marriott, the AACR’s headquarters hotel. Such requests will be handled on a first-come, first-served basis and should be directed to the Meetings Department in the Association Office.

ASSISTANCE FOR HANDICAPPED REGISTRANTS

The AACR is committed to making its meeting accessible to all investigators. Registrants with special requirements for transportation, hotel accommodations, or other services connected with the meeting should inform the Association Office of their needs in advance of the meeting by contacting the Meetings Department in the Association Office as described in the first paragraph above.
Authors who submit an abstract of a paper for consideration for presentation at the Annual Meeting of the American Association for Cancer Research (AACR) confirm that they have not previously published this data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting. AACR policy states that the content of submitted abstracts is kept strictly confidential by the members of the Program Committee during the review and pre-publication process. After review of the abstract by the Program Committee, the PRESENTER will be notified about whether it has been accepted for presentation. The PRESENTER of the abstract must be one of the authors of the abstract, and it is expected that he or she will be the first author. Only those abstracts that are deemed acceptable for presentation by the Program Committee will be published in the *Proceedings of the American Association for Cancer Research*, which will be published in March 1999.

The paper presented at the annual meeting must coincide directly with the scientific content of the abstract submitted and determined to be acceptable by the Program Committee. If for any reason this is not possible, the paper must be withdrawn from presentation. Any requests for withdrawal of an abstract must be made in writing by the SPONSOR or PRESENTER.

**NOTE:** Authors will be assessed a charge for any extraordinary costs incurred as a result of the withdrawal of abstracts after the *Proceedings* issue is in production.

To provide a well-organized, effective scientific program, the Program Committee will have full discretion to assign papers to minisymposia, poster discussion sessions, and poster sessions.

**Minisymposia.** Minisymposia will be planned from submitted abstracts. This format serves as a vehicle for the presentation and extensive discussion of developments in timely areas of cancer research.

Authors whose papers are assigned to minisymposia will be informed about the amount of time available for the delivery of their papers. At appropriate intervals, there will be opportunities for the discussion of each paper presented during the session. In addition, these sessions may include an invited talk to bring the subject into current perspective; there will be an introduction and a concluding discussion of the topic.

**Poster Discussion Sessions.** Poster discussion sessions will be scheduled from submitted abstracts and will run for four hours. The presentation of posters is supplemented by a focused discussion of the research areas under consideration. After presentation of the posters, there will be a one-hour discussion period led by two chairpersons with expertise in the area. Participants will have an opportunity to view the posters again after the discussion.

Prior to the annual meeting, the two chairpersons of these sessions will communicate directly with the authors presenting in the session to obtain more information on the work to be discussed. Authors will be expected to submit the content of their posters to the two chairpersons in advance of the meeting to make the ensuing discussion more effective.

**Poster Sessions.** Regular poster sessions will extend for four hours. Authors will be required to present at their posters for the first three hours of the session. Detailed instructions for the preparation of posters will be sent to all authors whose abstracts are accepted for these sessions.

**Late-Breaking Research Session.** The firm deadline for submission of abstracts for publication in the *Proceedings of the American Association for Cancer Research* and for presentation at one of the regular sessions at the annual meeting is November 6, 1998. In addition, the AACR will provide an opportunity for the presentation of a few definitive reports of timely and highly significant research findings that become available after the November 6 abstract deadline. The work to be presented in this session must be of major novelty and importance, e.g., the characterization of a new gene in familial cancer or the discovery of a new diagnostic marker. Complete instructions for submission of these abstracts will appear in a forthcoming AACR Annual Meeting announcement and in AACR journals in January 1999. The deadline for submission of abstracts for consideration for the Late-Breaking Research Session will be March 12, 1999.

**Scheduling of Presentations.** The AACR will do its utmost to assist any author who, for religious reasons, cannot present a paper on a particular day of the week. However, the complexities of scheduling thousands of papers for this multidisciplinary cancer research meeting require that sufficient notice from authors be given to the Program Committee. Authors who need special assistance with regard to the scheduling of their papers must enclose written requests along with their submitted abstracts.

**SPONSORSHIP REGULATIONS**

1. The SPONSOR must be a member of the Association in good standing. That is, an active, corresponding, or associate member must have paid his or her membership dues through 1998 by the time of the submission of the abstract in order to serve as the SPONSOR of one abstract for the upcoming annual meeting. As stated in the AACR By-Laws, honorary and emeritus members are exempt from the payment of dues; thus this regulation does not apply to them.

2. Each member of the AACR may SPONSOR only one abstract. There are no exceptions to this regulation. This privilege may be used in one of two ways: (a) the SPONSOR may be one of the authors of the abstract, or (b) the SPONSOR may sign the abstract form on behalf of the authors who may be either members or nonmembers of the AACR.

3. Each submitted abstract must carry the SPONSOR’S AACR Member Number. This number appears on the AACR Membership Card and below the member’s name in the 1997-1998 AACR *Directory of Members*. The SPONSOR must sign the abstract form.
4. A member or nonmember may be listed as a coauthor on more than one abstract, provided that each abstract has a different member SPONSOR.

5. The SPONSOR is obligated to ascertain that all authors are aware of the content of the abstract. Sponsorship of an abstract implies support for the data and the interpretations contained therein.

Special Limitations on Submissions by Associate Members. An associate member in good standing may SPONSOR his or her own abstract provided that (a) he or she is the PRESENTER of the abstract, and (b) an active or corresponding member in good standing also signs the abstract form ENDORSING the work. The ENDORSER does not thereby lose his or her own sponsorship privilege. NOTE: An associate member may SPONSOR only one abstract, and he or she must also be the PRESENTER of that abstract.

COMPLIANCE WITH THESE REGULATIONS IS THE RESPONSIBILITY OF THE SPONSOR. Adherence to these rules will be verified. Violations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee.

INSTRUCTIONS FOR THE PREPARATION AND SUBMISSION OF ABSTRACTS

Each submitted abstract must carry the name, AACR Member Number, and signature of the SPONSOR on the appropriate lines of the abstract form. Each AACR member may SPONSOR only one abstract.

CONTENT OF ABSTRACTS

Authors who submit an abstract of a paper confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting.

Members of the Program Committee will evaluate the scientific quality of the submitted abstract on the basis of the following criteria: novelty of the research, significance of the findings, and clarity. Authors should be particularly cognizant of the importance of setting forth the objectives and hypotheses of the study in a clear, succinct manner and of summarizing the new, unpublished results. If the abstract is poorly written such that the Program Committee cannot determine its novelty and importance, the paper will not be accepted for presentation at the annual meeting.

1. Abstracts must describe in a succinct manner the purposes and results of the research so that the quality, originality, and comprehensiveness of the work can be evaluated by the Program Committee. Each abstract should contain: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions. Authors must accept sole responsibility for the statements in their abstracts. Abstracts should be carefully proofread to avoid errors in the published literature.

2. Titles should be indicative of the content of the abstract. All words necessary to identify the subject matter should be included in the title to facilitate electronic retrieval (CD-ROM or online searches). Avoid nonstandard abbreviations in abstract titles.

3. Abbreviations may be used in the body of an abstract if they are defined at their first mention in the text. Complex therapeutic regimens must be identified.

4. NOTE: The AACR is committed to the advancement of cancer research and the cure and prevention of cancer through the facilitation of communication and full dissemination of knowledge among scientists and others dedicated to the cancer problem. Therefore, the AACR requires strict compliance with the following regulation:

When biological or chemical data pertaining to chemical entities are an integral part of the research, the chemical structure, method of preparation, and patent or reference numbers must be presented. If for any reason this information cannot be given when the paper is presented at the annual meeting, the abstract on this work should not be submitted for consideration.

5. Because of administrative and time constraints, supplemental data submitted along with the abstract cannot be transmitted to the Program Committee for review.

GENERAL INSTRUCTIONS FOR THE SUBMISSION OF ABSTRACTS

The AACR will not accept abstracts for the 1999 Annual Meeting via Internet submission or by fax or e-mail delivery. Abstracts must be submitted on the official 1999 AACR abstract form. Two abstract forms are enclosed. Please pass one on to a colleague if you do not need it for your own use. The blank form may also be photocopied for use by others. Additional abstract forms may be obtained by calling or writing to the AACR Office. The blank form is also available as a PDF document that can be downloaded and printed from the AACR Website: <http://www.aacr.org/meeting.htm>.

Instructions for completing the abstract form are given on the following pages.

The accuracy of the submitted abstract is the responsibility of the authors. Every effort will be made to publish the abstract exactly as submitted on the abstract form. Although abstracts will be typeset for print and electronic distribution, they will not be edited or corrected by AACR Staff. Therefore, authors should prepare and proofread their abstracts carefully prior to submission. Errors made on your submitted abstract are likely to appear in print.
A Temporary Abstract Number will be assigned to your abstract when it arrives at the AACR Office. This number will be listed on the card that is returned to you acknowledging receipt of your abstract. Please reference the Temporary Abstract Number in all subsequent communications with the AACR Office.

ABSTRACT FORM

The official abstract form must be filled out completely and signed in accordance with the instructions. Three (3) photocopies of the completed form must also be submitted. In addition to typing the abstract within the box according to the instructions given below, please provide the information and signatures requested on the abstract form and accompanying materials as follows. (NOTE: The numbered headings below correspond to the numbers on the abstract form.)

1. Category and Subclassification. Choose ONLY ONE category and subclassification. Indicate the category and subclassification in which your paper belongs by typing the appropriate five-character code in the blocks provided. A list of codes for the categories and subclassifications appears on Pages 10-12 of this booklet. The list is also available at the AACR Website. These designations will serve as a guide to the Program Committee in the grouping of abstracts but will not necessarily be the actual titles of scientific sessions to be held at the annual meeting.

2. Sponsor of the Abstract. Type the AACR member number, name, address, telephone and FAX numbers, and e-mail address of the member using his or her membership privilege to SPONSOR the abstract. (Member numbers can be found on an individual's membership card and in the 1997-1998 AACR Directory of Members.) The SPONSOR, who must be a member of the AACR in good standing through 1998, may SPONSOR only one abstract. (See Page 5 for Sponsorship Regulations.)

3. Sponsor Signature. The SPONSOR must sign the form in the space provided to indicate support for the data and interpretations contained in the abstract.

4. Associate Members Only. If an associate member is the SPONSOR AND PRESENTER of the abstract, he or she must ask an active or corresponding member in good standing or an emeritus or honorary member to sign Line 4 of the form as the ENDORSER of the work. Type the name and member number of the ENDORSING member on the appropriate lines.

5. Eligibility for Young Investigator Awards for American and International Scientists.

A. The AACR is very grateful to the growing number of sponsors who help several hundred young investigators attend the annual meeting each year. International travel grants for young scientists are on the rise. For example, ITO EN, Ltd. is underwriting a major enhancement of the AACR's program of young investigator travel grants for Asian scientists and will continue its very generous support of this new program through 2002.

Submission of an abstract by the deadline of November 6 is an absolute prerequisite for receipt of any AACR travel award. Qualified scientists from all countries are therefore encouraged to submit abstracts and to indicate their eligibility for these awards by observing the following instructions: Indicate whether the PRESENTER of the abstract is a medical student, graduate student, physician in training, or postdoctoral fellow from an academic or governmental organization. PRESENTERS who meet these requirements and who are first authors on abstracts given high ratings for scientific merit by the Program Committee may be candidates for a young investigator award. If a PRESENTER is eligible based on the above criteria and is under consideration, a letter confirming his or her status, submitted on the official letterhead of the PRESENTER's institution and signed by the registrar, dean, or department head of that institution, will be requested at a later date.

B. Minority Scholar Awards in Cancer Research are available if the PRESENTER meets the above-mentioned criteria and is African American, Hispanic American, Native American, Alaskan Native, or Native Pacific Islander. Through a generous grant provided by the Comprehensive Minority Biomedical Program of the National Cancer Institute, funds are available to encourage participation in the annual meeting by minority groups which have traditionally been underrepresented in cancer and biomedical research. Eligible scientists are young, full-time predoctoral (graduate or medical) students, postdoctoral fellows, and physicians in training who are either engaged in cancer research, or who have training that could lead to contributions in this field. Only citizens of the United States and Canada or scientists who are permanent residents in these countries may receive one of these awards.

Although preference will be shown to authors of abstracts that have been accepted for presentation at the 1999 AACR Annual Meeting, this is not a requirement for the Minority Scholar award. Awardees will be selected on the basis of their qualifications, references from mentors, and an estimation of the potential professional benefit of their attendance at the annual meeting. An advisory committee consisting of senior members of the AACR carefully reviews submitted applications and letters of reference. The award will consist of partial support for the registration, travel, and subsistence expenses incurred in connection with their attendance at the annual meeting.

Persons checking this box will receive an application form which must be completed and returned to the AACR by December 4, 1998. Applicants will be chosen from both minority institutions and the larger body of universities, colleges, and research institutes. If accepted, applicants are expected to attend at least three full days of scientific sessions at the annual meeting and participate in all planned activities for the awardees. They are also required to submit a report commenting on the scientific sessions they attended at the annual meeting and on the Minority Scholar Program.

C. AACR-HBCU Faculty Awards in Cancer Research are available to full-time faculty members of Historically Black Colleges and Universities (HBCU's). Supported by a generous grant provided by the Comprehensive Minority Biomedical Program of the National Cancer Institute, these awards will be presented to scientists at the level of Assistant Professor or above at an HBCU who are engaged in meritorious basic, clinical, or translational cancer research. Awardees will receive financial support for their participation in the Annual Meeting up to a maximum of $1,500.

The purpose of this Award program is to increase the scientific knowledge base of faculty members at HBCU's and to encourage them and their students to pursue careers in cancer research. The selection of awardees will be made by a multidisciplinary AACR Award Committee consisting of experts in all aspects of basic, clinical, and translational research. Although preference will be shown to authors of abstracts that have been accepted for presentation at the 1999 AACR Annual Meeting, this is not a requirement for the AACR-HBCU Faculty Awards. Other selection criteria will include the candidate's publications and current grant support as evidence of a
commitment to and of achievement in cancer research. The Committee will also assess the specific benefits that the candidate will derive from attendance at the meeting with particular attention to the candidate’s own statement in this regard.

Persons checking this box will receive an application form which must be completed and returned to the AACR by December 4, 1998. If accepted, applicants are expected to attend at least three full days of scientific sessions at the annual meeting and to participate in all planned activities for awardees. Reimbursement of meeting expenses is contingent upon submission of a report commenting on the scientific sessions they attended and on the AACR-HBCU Faculty Award Program.

6. Presenter of the Abstract. Type the name, AACR member number (if applicable), address, telephone and FAX numbers, and e-mail address of the PRESENTER of the paper in the space provided. The PRESENTER must be one of the authors of the abstract. It is expected that the first author of an abstract will be its PRESENTER.

7. Presenter Signature. The PRESENTER of the paper must sign the form in the space provided to acknowledge that the Copyright Transfer/Conflict of Interest Disclosure Form has been completed, and to give the AACR permission to arrange for audiotape recording and the subsequent sale of audiotape cassettes of the papers delivered orally at the 1999 AACR Annual Meeting. Your advance permission for taping in the event that your paper is among those to be recorded is appreciated.

8. Payment of US$40 Abstract Submission Fee. Please indicate your method of payment. Remember to list the name of the PRESENTER on your enclosed check. If you want the Abstract Submission Fee (US$40) to be billed to your credit card, please fill in the necessary information and sign in the space provided. Purchase orders cannot be accepted.

Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without the required signatures, will result in an additional fee of US$40, which will be billed to the SPONSOR.

FORMAT OF ABSTRACTS
Abstracts will be typeset from the paper copy of the abstract form. The accuracy of the submitted abstract is the responsibility of the authors. Careful preparation and proofreading are essential prior to submission. Every effort will be made to publish the abstract exactly as submitted on the abstract form, except in certain instances where changes are made to comply with AACR style. AACR does not assume responsibility for proofreading or correcting any scientific, grammatical, or typographical errors. Therefore, errors made in your submitted abstract are likely to appear in print.

Only abstracts submitted on the official 1999 abstract form will be considered by the Program Committee. Before typing the abstract on the form, read all instructions and examine the sample abstract thoroughly. Prepare your abstract in accordance with the approved format shown in the sample abstract (Page 14). Please note in particular the following regulations concerning format:

Dimensions: The entire abstract, including text, title, authors, and affiliations, must fit within the box provided on the abstract form. The dimensions of the box are 5 inches (12.5 cm) wide x 4 inches (10 cm) high. Do not reduce the abstract mechanically to fit into the box. Type the abstract single spaced.

Type: Abstracts may be printed using laser or ink-jet printers with type no smaller than 10-point. Abstracts may also be prepared using typewriters or daisy-wheel printers with a sharp black ribbon and a printing element no smaller than 12-pitch (elite). Do not use dot matrix printers. Any symbols that must be drawn by hand should be drawn with black ink.

Title: Use boldface type for the title if possible. The first line of the title should be flush with the left margin of the abstract box. Capitalize only the first letter of the first word; type the rest in lower case except where lower case is incorrect, e.g., “DNA.” Avoid nonstandard abbreviations in the title. (See Cancer Research Instructions for Authors, Vol. 58: 180-186, 1998, for a list of standard abbreviations.) Type a period at the end of the title.

Authors’ Names: Type the authors’ names as a group. For each author, type surname first followed by given name and initials. Omit academic degrees. Do not use footnote numbers or symbols after the authors’ names to refer to their individual affiliations. See next paragraph.

Affiliations: List affiliations as a group at the end of the list of authors’ names. For each affiliation, type the name of the institution, city, state (in abbreviated form), zip code, and country (other than the U.S.). Separate each affiliation with a semicolon. An example appears below:

Moody, T.W., Cassibang, M., Rosenstein, J., Gozes, Y., Ben Av, P., and Hla, T. Division of Clinical Sciences, National Cancer Institute, Rockville, MD 20850; Israel Institute for Biological Research, Neu-Ziona, 74100 Israel; and Holland Laboratory, American Red Cross, Rockville, MD 20855.

We prefer that you do not key the affiliation of each author to his/her name. However, if you are obligated to do so, DO NOT use footnote numbers or symbols after an author’s name to refer to his/her affiliation because they are difficult to distinguish in print. Instead, put the author’s initials in parentheses at the end of his/her affiliation as shown below:

Iwamura, T., Caffrey, T.C., Kawano K., Yamanari, H., Setoguchi, T., and Hollingsworth, M.A. Miyazaki Prefectural General Hospital, Miyazaki 880, Japan (T.I.); The Ellipey Institute for Research in Cancer and Allied Diseases, Omaha, NE 68198 (T.I., T.C.C., M.A.H.); and Miyazaki Medical College, Miyazaki 889-16, Japan (T.I., K.K., H.Y., T.S.).

Text: Begin the text on a separate line after the affiliations. Type the text single spaced in one paragraph. Nonstandard abbreviations are permitted in the text of the abstract if they appear in parentheses immediately after the term being abbreviated at the first usage of that term in the text. Tables, charts, illustrations, halftones, and color photographs are not acceptable as part of your abstract and should not be submitted.

INSTRUCTIONS FOR COMPLETING THE COPYRIGHT TRANSFER/CONFLICT OF INTEREST DISCLOSURE FORM
All PRESENTERS must submit the signed original plus one copy of this completed form along with their abstracts.

Copyright Transfer. The PRESENTER of the paper, as an author of the abstract and on behalf of all authors, must check the appropriate box and sign this section of the form.

Conflict of Interest Disclosure. The AACR has applied for accreditation of the Annual Meeting as an educational activity
for Category 1 credits towards the Physician’s Recognition Award Program of the American Medical Association. The Accreditation Council for Continuing Medical Education requires that all PRESENTERS at accredited activities declare whether they have any financial or other interest which might be construed as resulting in an actual, potential, or apparent conflict of interest in the work presented. The AACR Board of Directors has accepted this principle and has made this declaration a prerequisite of abstract submission. The existence of financial interests or other relationships of a commercial nature is not regarded by the AACR as creating a presumption of impropriety. Rather, the AACR desires to make as much relevant information available as possible to those reviewing the data being presented.

All PRESENTERS, whether or not they have a financial interest in the work they intend to present, must complete and sign the Conflict of Interest Disclosure section of the form on Page 13 of this booklet. The form may also be downloaded as a PDF file from the AACR’s Website. Failure to submit this form along with an abstract form by November 6, 1998, will result in return of the abstract to the PRESENTER without consideration by the Program Committee.

MAILING INSTRUCTIONS

1. Abstracts must be received in the office of the American Association for Cancer Research no later than November 6, 1998. Submission at an earlier date would be appreciated. The AACR urges investigators working outside of the United States to send their abstracts well ahead of the deadline date or to use one of the international courier services that offer delivery within a few days. The deadline for receipt will be applied uniformly to all abstracts regardless of their origin. FAX or other electronic transmittals will not be accepted.

2. Enclose the following materials unfolded and with cardboard backing in an envelope of suitable size:
   A. An original plus three (3) legible copies of the completed abstract form signed by the SPONSOR and PRESENTER.
   B. A check for US$40 payable to the American Association for Cancer Research, Inc. All checks must be drawn on United States banks. PLEASE LIST THE NAME OF THE PRESENTER ON YOUR CHECK. If you wish us to charge this amount to your credit card, fill out and sign Item 8 on the abstract form. Purchase orders are not acceptable for payment of the abstract submission fee.
   C. The completed and signed Copyright Transfer/Conflict of Interest Disclosure Form plus one photocopy.
   D. The Acknowledgment Card attached to this announcement. The names of the authors and the title of the paper should be filled in on the card prior to submission. The card will be returned to you showing the Temporary Abstract Number assigned to your abstract. This number should be referenced in all correspondence or telephone calls to the AACR Office. PRESENTER: To ensure receipt of the Acknowledgment Card, put your own address on the reverse of the card and affix proper postage.

E. One stamped, regular letter-sized envelope (about 4 x 9.5 inches, 10.2 x 24.2 cm) addressed to the PRESENTER. The final decision of the Program Committee concerning acceptability for presentation and publication will be returned in this envelope along with any other necessary instructions.

3. Send the materials listed above together in one envelope to:
   American Association for Cancer Research, Inc.
   1999 ANNUAL MEETING ABSTRACT
   Public Ledger Building, Suite 826
   150 S. Independence Mall West
   Philadelphia, PA 19106-3483

4. Do not enclose membership application forms, membership dues, advance registration forms, housing forms, or any other materials in the envelope with your abstract submission. Please submit these documents separately and follow the particular mailing instructions provided on each one.

   Special mailing charges cannot be paid by the AACR. The AACR staff cannot assume responsibility for abstracts that are not delivered directly to the premises.

SUBMISSION OF CORRECTED ABSTRACTS

If after submitting your abstract you discover an error, please do not submit a corrected abstract until you have received an acknowledgment card containing the Temporary Abstract Number of your original submission. You may then submit a corrected abstract in strict accordance with the following instructions:

1. On a photocopy of the original abstract, indicate the correction(s) you are making.

2. On an official abstract form in the box provided, type the full text of the resubmitted abstract prepared according to the Format instructions above. Answer all the questions on the form.

3. Label both the original and resubmitted abstract forms in the upper right-hand corner with your Temporary Abstract Number and the word "Resubmission."

4. Send the corrected original abstract and an original and three copies of the resubmitted abstract on the official form to the address given above. Write or type the word “Resubmission” on the mailing envelope.

Authors will be charged for any extraordinary costs incurred as a result of abstracts being resubmitted or withdrawn after the Proceedings is in production. The AACR will not be responsible for the acceptance and processing of corrected abstracts that are not submitted in compliance with the above regulations. No substantive changes may be made in abstracts after they have undergone scientific review, and the AACR cannot accept any resubmission or comply with any request for withdrawal of an abstract that will delay the publication of the Proceedings.

THE NOVEMBER 6, 1998 DEADLINE WILL BE STRICTLY ENFORCED.
<table>
<thead>
<tr>
<th>BL</th>
<th>CELL AND TUMOR BIOLOGY</th>
<th>MB</th>
<th>MOLECULAR BIOLOGY</th>
</tr>
</thead>
<tbody>
<tr>
<td>BL1</td>
<td>Cell Growth Signaling Pathways: Cell Biology Aspects</td>
<td>MB1</td>
<td>Cancer Genetics I: New Loci and Mechanisms of Genomic Alterations</td>
</tr>
<tr>
<td></td>
<td>BL1-01 Growth factors: structure and function</td>
<td></td>
<td>New human cancer genes: mapping of loci and cloning</td>
</tr>
<tr>
<td></td>
<td>BL1-02 Receptors: structure and function</td>
<td></td>
<td>MB1-01 Molecular cytogenetics</td>
</tr>
<tr>
<td></td>
<td>BL1-03 Signaling: membrane to nucleus</td>
<td></td>
<td>MB1-02 Comparative genomic hybridization</td>
</tr>
<tr>
<td></td>
<td>BL1-04 Autocrine-paracrine signaling</td>
<td></td>
<td>MB1-03 LOH and marker studies</td>
</tr>
<tr>
<td></td>
<td>BL1-05 Physiology/organismal homeostasis</td>
<td></td>
<td>MB1-04 Familial cancer and linkage studies</td>
</tr>
<tr>
<td></td>
<td>BL1-06 Cell-matrix interactions</td>
<td></td>
<td>MB1-05 Functional cloning</td>
</tr>
<tr>
<td></td>
<td>BL1-07 Adhesion and cytoskeleton inputs</td>
<td></td>
<td>MB1-06 Expression cloning strategies</td>
</tr>
<tr>
<td></td>
<td>BL1-08 Cell-cell interactions: communication/GAP junctions</td>
<td></td>
<td>MB1-07 New mutation detection methods</td>
</tr>
<tr>
<td></td>
<td>BL1-09 Cell-cell adhesion receptors</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BL1-10 Tumor-stromal cell interactions</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BL1-11 Organogenesis and tumor development</td>
<td></td>
<td>MB1-08 Mechanisms of genomic alterations</td>
</tr>
<tr>
<td></td>
<td>BL1-12 Cell and tissue kinetics/physiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BL1-13 Tissue remodeling and regeneration</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BL1-14 Wound healing and tissue repair</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BL1-15 Animal models of tissue host-tumor interactions</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BL1-16 Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BL2</td>
<td>Cell Death Signaling</td>
<td>MB2</td>
<td>Cancer Genetics II: Tumor Suppressor Genes -- Structure and Function</td>
</tr>
<tr>
<td></td>
<td>BL2-01 Transcriptional control of apoptosis</td>
<td></td>
<td>New mutations in human tumors</td>
</tr>
<tr>
<td></td>
<td>BL2-02 Genetic and developmental controls</td>
<td></td>
<td>MB2-02 Genotypic/phenotype correlations</td>
</tr>
<tr>
<td></td>
<td>BL2-03 Receptor coupled signaling to apoptosis</td>
<td></td>
<td>New functional aspects of selected known tumor suppressor genes</td>
</tr>
<tr>
<td></td>
<td>BL2-04 Death protein networks</td>
<td></td>
<td>MB2-03 p53</td>
</tr>
<tr>
<td></td>
<td>BL2-05 ICE proteases/caspases: cascades/substrates</td>
<td></td>
<td>MB2-04 Rb and family</td>
</tr>
<tr>
<td></td>
<td>BL2-06 Caspase inhibitors: experimental and preclinical</td>
<td></td>
<td>MB2-05 WR1</td>
</tr>
<tr>
<td></td>
<td>BL2-07 Enzymology of apoptosis</td>
<td></td>
<td>MB2-06 NFI/NF2</td>
</tr>
<tr>
<td></td>
<td>BL2-08 Nuclear target/effectors of apoptosis</td>
<td></td>
<td>MB2-07 VHL</td>
</tr>
<tr>
<td></td>
<td>BL2-09 Growth factors and other survival signals</td>
<td></td>
<td>MB2-08 DCC</td>
</tr>
<tr>
<td></td>
<td>BL2-10 Cell adhesion/cell-cell interactions in apoptosis</td>
<td></td>
<td>MB2-09 APC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MB2-10 BRCA1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MB2-11 BRCA2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MB2-12 Other</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MB2-13 New tumor suppressor genes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MB2-14 Suppressors of metastasis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MB2-15 Tumor suppressor networks - functional pathways</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MB2-16 Other</td>
</tr>
<tr>
<td>BL3</td>
<td>Tumor Progression, Invasion, and Metastasis</td>
<td>MB3</td>
<td>Cancer Genetics III: Human and Retroviral Oncogenes -- Structure and Function</td>
</tr>
<tr>
<td></td>
<td>MB3-01 Growth factors and soluble molecules</td>
<td></td>
<td>Viral Oncogenes</td>
</tr>
<tr>
<td></td>
<td>MB3-02 Protein tyrosine kinases: receptor and nonreceptor</td>
<td></td>
<td>MB3-01 Growth factors and soluble molecules</td>
</tr>
<tr>
<td></td>
<td>MB3-03 Protein serine-threonine kinases: receptor and nonreceptor</td>
<td></td>
<td>MB3-02 Protein tyrosine kinases: receptor and nonreceptor</td>
</tr>
<tr>
<td></td>
<td>MB3-04 Phosphatases: receptor and nonreceptor</td>
<td></td>
<td>MB3-03 Protein serine-threonine kinases: receptor and nonreceptor</td>
</tr>
<tr>
<td></td>
<td>MB3-05 Cytosolic adaptors and intermediate molecules</td>
<td></td>
<td>MB3-04 Phosphatases: receptor and nonreceptor</td>
</tr>
<tr>
<td></td>
<td>MB3-06 Guanine nucleotide binding proteins and effectors</td>
<td></td>
<td>MB3-05 Cytosolic adaptors and intermediate molecules</td>
</tr>
<tr>
<td></td>
<td>MB3-07 Mitogenic signaling kinase cascades</td>
<td></td>
<td>MB3-06 Guanine nucleotide binding proteins and effectors</td>
</tr>
<tr>
<td></td>
<td>MB3-08 Oncogenic transcription factors</td>
<td></td>
<td>MB3-07 Mitogenic signaling kinase cascades</td>
</tr>
<tr>
<td></td>
<td>MB3-09 New oncogenes</td>
<td></td>
<td>MB3-08 Oncogenic transcription factors</td>
</tr>
<tr>
<td></td>
<td>MB3-10 New oncogene networks</td>
<td></td>
<td>MB3-09 New oncogenes</td>
</tr>
<tr>
<td></td>
<td>MB3-11 Other</td>
<td></td>
<td>MB3-10 Other</td>
</tr>
<tr>
<td></td>
<td>MB3-12 Viral Oncogenesis</td>
<td></td>
<td>MB3-11 Other</td>
</tr>
<tr>
<td></td>
<td>MB3-13 Human tumor viruses: etiology/epidemiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB3-14 Molecular biology and genetics of viruses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MB4</td>
<td>Gene Expression and Epigenetic Regulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB4-01 Cancer genome anatomy: comparative genomics</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB4-02 New methods in tumor microdissection/comparative expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB4-03 DNA methylation and maintenance</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB4-04 Enzymology of DNA methylation/ modification</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB4-05 Imprinting and allele-specific expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB4-06 Silencing and reactivation of gene expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB4-07 Telomeres and telomerase</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB4-08 Cellular aging and senescence: molecular studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MB5</td>
<td>Gene Regulation and Transcriptional Control of the Cancer Phenotype</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-01 Basic mechanisms of transcription: biochemistry/epidemiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-02 Transcription-coupled repair: genomics/biochemistry</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-03 Promoter/enhancer analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-04 Growth factor-inducible gene expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-05 Oncogenic transcription factor function: leukemias/lymphomas/solid tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-06 Transgenic models of promoter and transcription factor function</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-07 Protein-protein interaction in transcription factor function</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-08 Protein phosphorylation and control of gene expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-09 Transcriptional control of cell differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-10 Transcriptional programs and organogenesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-11 Chromatin structure/higher order regulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-12 Gene position effects and genomic setting</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-13 Antisense control of gene expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-14 Posttranscriptional and control</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-15 New methods for multiplex analysis of gene expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-16 Structural biology of transcription factors</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB5-17 Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BL6</td>
<td>Cell Cycle</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB6-01 Growth factor control of cell cycle</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB6-02 Genetic control of cell cycle progression</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB6-03 Cell cycle genetic alterations</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB6-04 Cell cycle checkpoints</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB6-05 Checkpoint: genetics and biochemistry</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB6-06 Cyclins and CDKs</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB6-07 CDK inhibitors</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB6-08 Phosphorylation and proteolysis in cell cycle control</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB6-09 Negative regulation of cell cycle</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB6-10 Viral oncoproteins and cell cycle regulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MB6-11 Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CG</td>
<td>CARCINOGENESIS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CG1</td>
<td>Biomarkers, Premalignant Lesions, and Risk Assessment</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CG1-01 Biomarkers of exposure to carcinogens</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CG1-02 Environmental carcinogenesis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CG1-03 Carcinogenesis in fish models
CG1-04 Genetic susceptibility and risk assessment
CG1-05 Predictive assays for carcinogenesis
CG1-06 Premalignant lesions
CG1-07 Toxicology and carcinogenesis
CG1-08 Drug metabolizing enzymes
CG1-09 GSH/GST
CG1-10 Other

CG2 Molecular Carcinogenesis:
Metabolism, DNA Lesions, Mutagenesis, and DNA Repair
CG2-01 Biochemical aspects of carcinogen function: enzymatic bioactivation
CG2-02 Biochemistry of DNA repair
CG2-03 DNA adducts: identification and conformational effects
CG2-04 DNA adducts: repair and sequence specificity
CG2-05 Genetic and cyogenetic alterations
CG2-06 Metabolism and activation of carcinogens in animal models and humans
CG2-07 Molecular responses to DNA damage
CG2-08 Mutagenesis
CG2-09 Mutational spectrum of carcinogens
CG2-10 Oxygen radicals
CG2-11 Other

CG3 Promotion and Progression
CG3-01 Cellular transformation
CG3-02 Growth factors in progression
CG3-03 Mesenchymal/epithelial interactions
CG3-04 Signal transduction
CG3-05 Tumor promotion and progression
CG3-06 Other

EP EPIDEMIOLOGY
EP1 Analytical Epidemiology in Populations
EP1-01 Behavioral epidemiology
EP1-02 Cancer in minority and medically underserved populations
EP1-03 Diet, nutrition, and lifestyle factors
EP1-04 Environmental and occupational etiology
EP1-05 Radiation exposure and cancer risk
EP1-06 Gene-environment interactions
EP1-07 Human tumor viruses and other infectious agents in susceptible populations
EP1-08 Genetic polymorphisms and metabolizing enzymes
EP1-09 Premalignant lesions
EP1-10 Methodology, computer modeling, and biostatistics
EP1-11 Other

EP2 Molecular and Genetic Epidemiology
EP2-01 Genetic markers and biomarkers in epidemiology
EP2-02 Familial cancer genetics
EP2-03 Cancer syndromes
EP2-04 Genotype/phenotype correlations in cancer families
EP2-05 Susceptibility and risk assessment
EP2-06 Genetic counseling and ethical issues
EP2-07 Cancer surveillance in high-risk populations
EP2-08 Proactive cancer screening
EP2-09 Other

PR PREVENTION/BASIC SCIENCE AND CLINICAL STUDIES
PR1 Preclinical Prevention Studies: Markers and Mechanisms
PR1-01 Animal/transgenic models in promotion and prevention
PR1-02 Biological and biochemical mechanisms in prevention

PR1-03 Biomarkers and intervention studies
PR1-04 Molecular markers in prevention research
PR1-05 Caloric restriction
PR1-06 Cellular models in prevention research
PR1-07 Chemoprevention
PR1-08 Diet, nutrition, and cancer
PR1-09 Genetic influences on diet and cancer
PR1-10 Genetic susceptibility and prevention
PR1-11 Hormones and chemoprevention
PR1-12 Modulation of arachidonic acid metabolism
PR1-13 Other

PR2 Clinical Prevention Studies
PR2-01 Biomarkers and intervention studies
PR2-02 Chemoprevention trials
PR2-03 Studies at the interface of cancer prevention and chemotherapy
PR2-04 Physiological and lifestyle effects on chemoprevention
PR2-05 Prevention clinical trials
PR2-06 Prevention of second cancers
PR2-07 Prevention studies in high-risk populations
PR2-08 Other

CL CLINICAL RESEARCH
CL1 Phase I-III Clinical Trials
CL1-01 AIDS-related malignancies
CL1-02 Brain/central nervous system cancers
CL1-03 Breast cancer
CL1-04 Colon and other gastrointestinal cancers
CL1-05 Head and neck cancers
CL1-06 Leukemias and lymphomas
CL1-07 Lung cancer
CL1-08 Melanoma and skin cancer
CL1-09 Ovarian and other gynecological cancers
CL1-10 Pediatric malignancies
CL1-11 Prostate and other genitourinary tract cancers
CL1-12 Sarcomas
CL1-13 Second cancers
CL1-14 Other

CL2 Organ-Site Specific Studies I:
Preclinical Research – Tumor Biology and Translational Research
AIDS-related malignancies
CL2-01 Brain/central nervous system cancers
CL2-02 Breast cancer
CL2-04 Colon and other gastrointestinal cancers
CL2-05 Head and neck cancers
CL2-06 Leukemias and lymphomas
CL2-07 Lung cancer
CL2-08 Melanoma and skin cancer
CL2-09 Ovarian and other gynecological cancers
CL2-10 Pediatric malignancies
CL2-11 Prostate and other genitourinary tract cancers
CL2-12 Sarcomas
CL2-13 Second cancers
CL2-14 Animal/transgenic models of molecular progression
CL2-15 Other

CL3 Organ-Site Specific Studies II:
Preclinical Research – Experimental Therapeutics
AIDS-related malignancies
CL3-01 Brain/central nervous system cancers
CL3-02 Breast cancer
CL3-04 Colon and other gastrointestinal cancers
CL3-05 Head and neck cancers
CL3-06 Leukemias and lymphomas
CL3-07 Lung cancer
CL3-08 Melanoma and skin cancer
CL3-09 Ovarian and other gynecological cancers
CL3-10 Pediatric malignancies
CL3-11 Prostate and other genitourinary tract cancers
CL3-12 Sarcomas
CL3-13 Second cancers
CL3-14 Animal/transgenic models of molecular progression
CL3-15 Other

CL4 Clinical Pharmacology/Modality-based Clinical Research
CL4-01 Clinical drug resistance
CL4-02 Clinical toxicology
CL4-03 Biodistribution/availability
CL4-04 Pharmaceuticals and monitoring
CL4-05 Prodrugs and activation strategies
CL4-06 Other

CL5 Molecular Biology/Molecular Oncology in the Clinic
CL5-01 Advances in genome scanning relevant to the clinic
CL5-02 Comparative genomic hybridization from the bench to the clinic
CL5-03 Cytogenetics and clinical molecular genetics
CL5-04 Minimal residual disease
CL5-05 Molecular markers of metastasis and progression
CL5-06 Oncogene-based molecular diagnosis and prognosis
CL5-07 Tumor staging: correlation of clinical and molecular markers
CL5-08 Other

CL6 Supportive Care, Psychosocial Aspects of Cancer, and Survivorship
CL6-01 Cancer information access and dissemination
CL6-02 Pain research
CL6-03 Palliative care
CL6-04 Psychosocial aspects of cancer
CL6-05 Survivorship research
CL6-06 Other

EN ENDOCRINOLOGY/PRECLINICAL AND CLINICAL
EN1 Molecular and Preclinical Endocrinology: Receptors and Signal Transduction
EN1-01 Cytokines and receptors
EN1-02 Growth factors and cell surface receptors
EN1-03 Developmental control of hormone receptors
EN1-04 Hormonal control of cell growth and death
EN1-05 Hormone action and inhibitors
EN1-06 Hormones and differentiation
EN1-07 Hormone receptor networks: signal transduction
EN1-08 Nuclear receptors: structure and function
EN1-09 New ligands
<table>
<thead>
<tr>
<th>EN1-10</th>
<th>Preclinical studies of endocrine-related cancers</th>
</tr>
</thead>
<tbody>
<tr>
<td>EN1-11</td>
<td>Protein-protein and co-factor interactions</td>
</tr>
<tr>
<td>EN1-12</td>
<td>Receptor crosstalk and signaling</td>
</tr>
<tr>
<td>EN1-13</td>
<td>Retinoids and receptors</td>
</tr>
<tr>
<td>EN1-14</td>
<td>Steroid hormones and receptors</td>
</tr>
<tr>
<td>EN1-15</td>
<td>Thyroid hormones and receptors</td>
</tr>
<tr>
<td>EN1-16</td>
<td>Other</td>
</tr>
<tr>
<td>EN2</td>
<td>Clinical Endocrinology</td>
</tr>
<tr>
<td>EN2-01</td>
<td>Hormonal carcinogenesis</td>
</tr>
<tr>
<td>EN2-02</td>
<td>Retinoid-based cancer therapy</td>
</tr>
<tr>
<td>EN2-03</td>
<td>Hormone receptors and diagnosis/prognosis</td>
</tr>
<tr>
<td>EN2-04</td>
<td>Hormone synthesis, metabolism, and inhibitors</td>
</tr>
<tr>
<td>EN2-05</td>
<td>Neuroendocrine and other endocrine factors</td>
</tr>
<tr>
<td>EN2-06</td>
<td>Breast</td>
</tr>
<tr>
<td>EN2-07</td>
<td>Ecotropic hormone production</td>
</tr>
<tr>
<td>EN2-08</td>
<td>Gynecological cancers</td>
</tr>
<tr>
<td>EN2-09</td>
<td>Prostate and other genitourinary tract cancers</td>
</tr>
<tr>
<td>EN2-10</td>
<td>Other</td>
</tr>
<tr>
<td>EN2-11</td>
<td>Other</td>
</tr>
<tr>
<td>IM</td>
<td>IMMUNOLOGY/PRECLINICAL AND CLINICAL</td>
</tr>
<tr>
<td>IM1</td>
<td>Tumor Immunobiology: Experimental and Preclinical</td>
</tr>
<tr>
<td>IM1-01</td>
<td>Animal/transgenic models for tumor immunology</td>
</tr>
<tr>
<td>IM1-02</td>
<td>Antigenic modulation</td>
</tr>
<tr>
<td>IM1-03</td>
<td>Cancer vaccines</td>
</tr>
<tr>
<td>IM1-04</td>
<td>DNA-based vaccines</td>
</tr>
<tr>
<td>IM1-05</td>
<td>Oncogene-directed immunotherapy/vaccines</td>
</tr>
<tr>
<td>IM1-06</td>
<td>Tumor suppressor-directed immunotherapy/vaccines</td>
</tr>
<tr>
<td>IM1-07</td>
<td>Viral immunology and vaccines</td>
</tr>
<tr>
<td>IM1-08</td>
<td>Immunodeficiency/immunosuppression (including AIDS and AIDS-related malignancies)</td>
</tr>
<tr>
<td>IM1-09</td>
<td>Immunomodulation</td>
</tr>
<tr>
<td>IM1-10</td>
<td>Integrins and cell adhesion molecules</td>
</tr>
<tr>
<td>IM1-11</td>
<td>Lymphokines, cytokines, and growth factors</td>
</tr>
<tr>
<td>IM1-12</td>
<td>Nonspecific effector mechanisms</td>
</tr>
<tr>
<td>IM1-13</td>
<td>Specific immunomechanisms</td>
</tr>
<tr>
<td>IM1-14</td>
<td>Tumor antigens</td>
</tr>
<tr>
<td>IM2</td>
<td>Clinical Immunology: Biological Therapy</td>
</tr>
<tr>
<td>IM2-01</td>
<td>Antibodies/immunoconjugates</td>
</tr>
<tr>
<td>IM2-02</td>
<td>Cancer vaccines</td>
</tr>
<tr>
<td>IM2-03</td>
<td>Cellular immunotherapy</td>
</tr>
<tr>
<td>IM2-04</td>
<td>Lymphokines and growth factors</td>
</tr>
<tr>
<td>IM2-05</td>
<td>Immunodiagnosis</td>
</tr>
<tr>
<td>IM2-06</td>
<td>Immunochemistry of human cancer</td>
</tr>
<tr>
<td>IM2-07</td>
<td>Transplantation: control of rejection</td>
</tr>
<tr>
<td>IM2-08</td>
<td>Other</td>
</tr>
<tr>
<td>PT</td>
<td>PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS</td>
</tr>
<tr>
<td>PT1</td>
<td>Drug Discovery: Design, Screening, and Delivery</td>
</tr>
<tr>
<td>PT1-01</td>
<td>Human xenograft models for drug discovery</td>
</tr>
<tr>
<td>PT1-02</td>
<td>Biochemical modulators of the therapeutic index</td>
</tr>
<tr>
<td>PT1-03</td>
<td>Combination chemotherapy</td>
</tr>
<tr>
<td>PT1-04</td>
<td>Differentiation therapy</td>
</tr>
<tr>
<td>PT1-05</td>
<td>Drug design: rational/empirical</td>
</tr>
<tr>
<td>PT1-06</td>
<td>Combinatorial chemistry-based drug design</td>
</tr>
<tr>
<td>PT1-07</td>
<td>Drug screening</td>
</tr>
<tr>
<td>PT1-08</td>
<td>Novel targets</td>
</tr>
<tr>
<td>PT1-09</td>
<td>Novel drug delivery systems</td>
</tr>
<tr>
<td>PT1-10</td>
<td>Other</td>
</tr>
<tr>
<td>PT2</td>
<td>Mechanisms of Drug Action</td>
</tr>
<tr>
<td>PT2-01</td>
<td>Cell cycle mechanisms for anticancer drug action</td>
</tr>
<tr>
<td>PT2-02</td>
<td>Cellular responses to anticancer drugs</td>
</tr>
<tr>
<td>PT2-03</td>
<td>Drug-mediated stimulation of cell death pathways</td>
</tr>
<tr>
<td>PT2-04</td>
<td>Intracellular targets</td>
</tr>
<tr>
<td>PT2-05</td>
<td>Modulation of DNA repair</td>
</tr>
<tr>
<td>PT2-06</td>
<td>Oncogenic transcription factors as targets</td>
</tr>
<tr>
<td>PT2-07</td>
<td>Secondary targets</td>
</tr>
<tr>
<td>PT2-08</td>
<td>Other</td>
</tr>
<tr>
<td>PT3</td>
<td>Drug Resistance: Multidrug Resistance</td>
</tr>
<tr>
<td>PT3-01</td>
<td>Biochemistry of membrane metabolism and transport</td>
</tr>
<tr>
<td>PT3-02</td>
<td>Drug transport and metabolism</td>
</tr>
<tr>
<td>PT3-03</td>
<td>Non-P-glycoprotein multidrug resistance</td>
</tr>
<tr>
<td>PT3-04</td>
<td>P-glycoprotein structure and function</td>
</tr>
<tr>
<td>PT3-05</td>
<td>Reversal of multidrug resistance (preclinical)</td>
</tr>
<tr>
<td>PT3-06</td>
<td>Other</td>
</tr>
<tr>
<td>PT4</td>
<td>Drug Resistance II</td>
</tr>
<tr>
<td>PT4-01</td>
<td>Drug transport and metabolism</td>
</tr>
<tr>
<td>PT4-02</td>
<td>Glutathione metabolism</td>
</tr>
<tr>
<td>PT4-03</td>
<td>Natural products, synthetic drugs, and nucleotide analogs</td>
</tr>
<tr>
<td>PT4-04</td>
<td>Novel mechanisms</td>
</tr>
<tr>
<td>PT4-05</td>
<td>Regulation of gene expression in drug resistance</td>
</tr>
<tr>
<td>PT4-06</td>
<td>Reversal of drug resistance</td>
</tr>
<tr>
<td>PT4-07</td>
<td>Other</td>
</tr>
<tr>
<td>PT5</td>
<td>Pharmacology and Preclinical Toxicology</td>
</tr>
<tr>
<td>PT5-01</td>
<td>Cellular pharmacology</td>
</tr>
<tr>
<td>PT5-02</td>
<td>Pharmacogenetics</td>
</tr>
<tr>
<td>PT5-03</td>
<td>Pharmacokinetics and pharmacodynamics</td>
</tr>
<tr>
<td>PT5-04</td>
<td>Preclinical toxicology</td>
</tr>
<tr>
<td>PT5-05</td>
<td>Other</td>
</tr>
<tr>
<td>PT6</td>
<td>Therapeutic Agents: Small Molecule Approaches</td>
</tr>
<tr>
<td>PT6-01</td>
<td>Alkylating agents</td>
</tr>
<tr>
<td>PT6-02</td>
<td>Alkylating agents</td>
</tr>
<tr>
<td>PT6-03</td>
<td>Cerebroprotective therapeutic agents</td>
</tr>
<tr>
<td>PT6-04</td>
<td>Other lipids</td>
</tr>
<tr>
<td>PT6-05</td>
<td>Farnesyl transferase inhibitors</td>
</tr>
<tr>
<td>PT6-06</td>
<td>Novel antitumor agents</td>
</tr>
<tr>
<td>PT6-07</td>
<td>Oncogene-based therapeutics: small molecules</td>
</tr>
<tr>
<td>PT6-08</td>
<td>Platinum complexes</td>
</tr>
<tr>
<td>PT6-09</td>
<td>Tyrosine kinase and phosphatase inhibitors</td>
</tr>
<tr>
<td>PT6-10</td>
<td>Other</td>
</tr>
<tr>
<td>PT7</td>
<td>Therapeutic Agents: Biological Approaches</td>
</tr>
<tr>
<td>PT7-01</td>
<td>Antitumor agents</td>
</tr>
<tr>
<td>PT7-02</td>
<td>Antitumor oligonucleotides</td>
</tr>
<tr>
<td>PT7-03</td>
<td>Antiangiogenic therapy</td>
</tr>
<tr>
<td>PT7-04</td>
<td>Apoptosis: therapeutic manipulation</td>
</tr>
<tr>
<td>PT7-05</td>
<td>Growth factor receptors and other surface antigens as targets for therapy</td>
</tr>
<tr>
<td>PT7-06</td>
<td>Oncogenes, tumor suppressor genes, and gene products as targets for therapy</td>
</tr>
<tr>
<td>PT7-07</td>
<td>Protein kinases and phosphatases as targets for therapy</td>
</tr>
<tr>
<td>PT7-08</td>
<td>Other</td>
</tr>
<tr>
<td>PT8</td>
<td>Experimental Gene Therapy</td>
</tr>
<tr>
<td>PT8-01</td>
<td>Vector systems and targeting strategies</td>
</tr>
<tr>
<td>PT8-02</td>
<td>Cell-type targeted vectors</td>
</tr>
<tr>
<td>PT8-03</td>
<td>TK-based suicide gene therapy</td>
</tr>
<tr>
<td>PT8-04</td>
<td>Cell-type specific expression regulation of suicide genes</td>
</tr>
<tr>
<td>PT8-05</td>
<td>Antisense/ribozyme decoys</td>
</tr>
<tr>
<td>PT8-06</td>
<td>Delivery systems: nonbiological, e.g., liposomes</td>
</tr>
<tr>
<td>PT8-07</td>
<td>Hematopoietic progenitor cell targeting</td>
</tr>
<tr>
<td>PT8-08</td>
<td>Other</td>
</tr>
<tr>
<td>PT9</td>
<td>Topoisomerases, Other DNA-Reactive Agents, and Tubulin Agents</td>
</tr>
<tr>
<td>PT9-01</td>
<td>DNA-reactive agents</td>
</tr>
<tr>
<td>PT9-02</td>
<td>Topoisomerases</td>
</tr>
<tr>
<td>PT9-03</td>
<td>Tubulin agents</td>
</tr>
<tr>
<td>PT9-04</td>
<td>Other</td>
</tr>
</tbody>
</table>

**RR** RADIATION ONCOLOGY

| RR1    | Experimental Radiobiology |
| RR1-01 | ATM: structure-function |
| RR1-02 | ATM: genomic aspects and mutations |
| RR1-03 | Cell cycle, differentiation, and apoptosis in radiation responses |
| RR1-04 | Cytogenetic responses to radiation |
| RR1-05 | DNA damage, mutagenesis, and repair |
| RR1-06 | Experimental radiotherapeutics |
| RR1-07 | Genetic and epigenetic control of radiosensitivity |
| RR1-08 | Hyperthermia |
| RR1-09 | Membrane targets for radiation |
| RR1-10 | Molecular mechanisms/radiation-induced gene expression |
| RR1-11 | Radiobiology |
| RR1-12 | Radiodynamic therapy |
| RR1-13 | Predictive assays for radiation sensitivity |
| RR1-14 | Oncogenes and tumor suppressor genes in radiation responses |
| RR1-15 | Radiation-induced biochemical alterations: conformation and function |
| RR1-16 | Radiation-induced transformation and carcinogenesis |
| RR1-17 | Radiation resistance |
| RR1-18 | Radiolabelled antibodies in diagnosis and localization |
| RR1-19 | Radioprotectors and radiosensitizers |
| RR1-20 | Tumor oxygenation and modification |
| RR1-21 | Other |

**Radiation Oncology: Preclinical and Clinical**

| RR1-22 | Clinical radiotherapeutic studies |
| RR1-23 | Combination therapies |
| RR1-24 | Drug/radiation interactions |
| RR1-25 | Modification of radiation sensitivity and injury |
| RR1-26 | Radiation-induced late effects - second cancers |
| RR1-27 | Radiation resistance |
| RR1-28 | Radiolabelled antibodies in diagnosis and localization |
| RR1-29 | Radioprotectors and radiosensitizers |
| RR1-30 | Other |
COPYRIGHT TRANSFER/CONFLICT OF INTEREST DISCLOSURE FORM

Your abstract cannot be considered unless this form is completed, signed, and enclosed with your submitted abstract.

NAME OF PRESENTER:

TITLE OF ABSTRACT:

COPYRIGHT TRANSFER

As the PRESENTER and as an author of this abstract, on behalf of all the authors (check appropriate box and affix signature):

☐ I hereby transfer copyright of this abstract to the American Association for Cancer Research (AACR), Inc., in the event that this abstract is published in the Proceedings of the American Association for Cancer Research. I understand by this transfer that the authors relinquish all exclusive rights of copyright ownership to the abstract, including without limitation all rights of reproduction, derivation, distribution, sale, and display of the work, in whole or in part, in any and all forms of media now or hereafter known. I understand the AACR, Inc., as copyright owner, has sole authority to grant permission to reproduce the abstract.

☐ This abstract was prepared by an employee or employees of the United States Federal Government. Therefore, I am unable to transfer rights to AACR, Inc.

__________________________________________________________
Signature of Presenter

__________________________________________________________
Date

DISCLOSURE STATEMENT FOR CONTINUING MEDICAL EDUCATION FACULTY

The American Association for Cancer Research (AACR) is committed to ensuring the integrity of its scientific, educational, and research programs and therefore requires disclosure of any financial or other interests which might be construed as resulting in an actual, potential, or apparent conflict. The existence of financial interests or other relationships of a commercial nature is not regarded by the AACR as creating a presumption of impropriety. Rather, AACR's policy represents a recognition of the many factors that can influence judgments about research data and a desire to make as much information as possible available to those reviewing the data.

All faculty participating in an educational activity are expected to disclose to the activity audience any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. (Significant financial interest or other relationship can include such things as grants or research support, employee, consultant, major stockholder, member of speakers bureau, etc.) The intent of this disclosure is not to prevent a speaker with a significant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion.

The PRESENTER is responsible for providing disclosure information for the PRESENTER and all CO-AUTHORS listed on the abstract. The PRESENTER'S signature verifies that all authors have read the Disclosure Statement and that appropriate disclosures have been documented.

I. a. Will your presentation/abstract include discussion of any commercial products or services? Yes ___ No ___

b. If Yes, do you or any of your co-authors have a significant financial interest or other relationship with the manufacturer(s) of any of the products or provider(s) of any of the services you intend to discuss? Yes ___ No ___

If Yes, please list the manufacturer(s) or provider(s) and describe the nature of the relationship(s). (Attach additional sheets as required.)

Author/Co-author Name Company Name Nature of Relationship
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

II. Will the presentation/abstract include information about unlabeled or investigational uses of commercial products? Yes ___ No ___

If Yes, please identify the commercial products and unlabeled or investigational uses. (Attach additional sheets as required.)

Product Unlabeled/Investigational Use(s)
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

Submitted by: ____________________________________________________________

(Print or Type Name) Fax# ________________

Signature ________________________________________________________________

Date __________________________
ABSTRACT FORM

AACR Annual Meeting
April 10-14, 1999
Philadelphia, PA


This study is part of an effort to develop effective chemoprevention for carcinogenesis of the lung. The current study explores aerosol administrations for this purpose. The agent selected for study is the synthetic glucocorticoid, budesonide. A nose-only aerosol technique has been developed which entails nebulization of budesonide dissolved in ethanol and subsequent stripping off the solvent. The size range of the budesonide particles produced by the apparatus has mass median aerodynamic diameter of less than 1 µm. An experiment in which the inhibitor is delivered as aerosolized budesonide, given for 1 minute, 6 times a week has been carried out. Concentrations of budesonide of 26, 81 and 148 µg/liter of air (calculated doses of 23, 72 and 126 µg/Kg body weight) were used. The aerosols were started 1 week after 3 oral administrations of benz[a]pyrene 2 mg/20Gm body weight to female A/J mice. All 3 doses of budesonide resulted in over 80% inhibition of pulmonary tumor formation, as compared to the aerosol control, and 90% or greater compared to mice not exposed to aerosol. The difference in inhibition is due to the aerosol procedure itself producing a reduction in tumor formation. A decrease in splenic weight (evidence of a systemic effect) occurred at all doses of budesonide. To the best of our knowledge, this is the first published effort at the use of aerosol administrations to prevent neoplasia of the lung. The results show that administration of budesonide by aerosol can prevent pulmonary carcinogenesis in female A/J mice.

Type abstract within black lines. See sample abstract.

6. Abstract is to be PRESENTED by 3676 Member No. (If an AACR Member.)

Lee W. Wattenberg

Name

(If Print)

Dept. of Lab. Med. & Pathology

Address

321 Church St. S.E., Jackson 6-133

Minneapolis, MN

City, State

55455 Zip/Postal Code

USA Country

(612) 625-1443 Telephone No. (612) 625-1447 Fax No.

watte002@maroon.tc.umn.edu E-Mail Address

7. As the PRESENTER and as an author of this abstract and on behalf of all the authors, I hereby give exclusive permission to the American Association for Cancer Research, Inc. to use my presentation at the 1999 Annual Meeting and to collect all revenue from subsequent audiocassette sales. I also acknowledge that I am enclosing a completed, signed original and 1 copy of the Copyright Transfer/Conflict of Interest Disclosure Form.

Lee W. Wattenberg

Signature of PRESENTER


X Check is enclosed. Please list name of PRESENTER on the check.

I authorize you to charge my credit card for the abstract submission fee.

VISA MasterCard American Express

Card No.

Expiration Date

Cardholder Name (PRINT) Signature
ABSTRACT FORM
AACR Annual Meeting
April 10-14, 1999
Philadelphia, PA

Deadline: November 6, 1998
Enclose:
- Original abstract form plus 3 photocopies. (This form must be filled out completely. Requested signatures must appear on all copies.)
- Check for US$40 payable to AACR, Inc., OR authorization to charge US$40 to credit card (see Item 8, below).
- A completed and signed original plus 1 copy of the Copyright Transfer/Conflict of Interest Disclosure Form
- Acknowledgment Card (completed and stamped).
- A self-addressed, stamped envelope.

1. Category and Subclassification
(see Pages 10-12): Type the five-character code in the blocks provided, for example,

<table>
<thead>
<tr>
<th>Category</th>
<th>Subclassification</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. Abstract is SPONSORED by: ____________________________ Member No.
(See Directory of Members for Member No.)

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3. As the SPONSOR of this abstract and on behalf of all the authors, I hereby indicate my support for the data contained herein. Signature of SPONSOR

4. (Complete only if SPONSOR is an Associate Member) I, the undersigned Active or Corresponding Member in good standing, Emeritus Member, or Honorary Member, endorse the content of this abstract, for which the above-named Associate Member is sponsor and presenter. (See regulations applying to Associate Members on Page 5.)

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5. Eligibility for Annual Meeting Awards (American and International)

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A. The PRESENTER of this abstract is a medical or graduate student, physician in training, or postdoctoral fellow.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B. The PRESENTER meets the criteria in Box A above and is also a minority scientist as defined by the National Cancer Institute (see Page 7).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. The PRESENTER of this abstract is a full-time faculty member at a Historically Black College or University (HBCU).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

6. Abstract is to be PRESENTED by: ____________________________ Member No.
(If an AACR Member.)

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

7. As the PRESENTER and as an author of this abstract and on behalf of all the authors, I hereby give exclusive permission to the American Association for Cancer Research, Inc. to record my presentation at the 1999 Annual Meeting and to collect all revenue from subsequent audiocassette sales. I also acknowledge that I am enclosing a completed, signed original and 1 copy of the Copyright Transfer/Conflict of Interest Disclosure Form.

Signature of PRESENTER


- Check is enclosed. Please list name of PRESENTER on the check.
- I authorize you to charge my credit card for the abstract submission fee.

<table>
<thead>
<tr>
<th>Card No.</th>
<th>Expiration Date</th>
</tr>
</thead>
</table>

Cardholder Name (PRINT) ____________________________ Signature ____________________________

Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without the required signatures, will result in a fee of US$40 which will be billed to the SPONSOR.
**ABSTRACT FORM**

**AACR Annual Meeting**  
**April 10-14, 1999**  
**Philadelphia, PA**

**DO NOT FOLD**

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CK</td>
<td>Other</td>
</tr>
<tr>
<td>/ NP</td>
<td>/ NP</td>
</tr>
</tbody>
</table>

**Deadline: November 6, 1998**  
**Enclose:**  
- Original abstract form plus 3 photocopies. (This form must be filled out completely. Requested signatures must appear on all copies.)  
- Check for US$40 payable to AACR, Inc. OR authorization to charge US$40 to credit card (see Item 8, below).  
- A completed and signed original plus 1 copy of the Copyright Transfer/Conflicts of Interest Disclosure Form  
- Acknowledgment Card (completed and signed).  
- A self-addressed, stamped envelope.

**1. Category and Subclassification**  
(see Pages 10-12): Type the five-character code in the blocks provided, for example,

- □ □ □ □ □  
- □ □ □ □ □

**2. Abstract is SPONSORED by:**  
**Member No.**  
(Please Print)  
Name  
Address  
City, State  
Zip/Postal Code  
Telephone No.  
E-Mail Address

**3. As the SPONSOR of this abstract and on behalf of all the authors, I hereby indicate my support for the data contained herein.**  
Signature of SPONSOR

**4. (Complete only if SPONSORED is an Associate Member) I, the undersigned Active or Corresponding Member in good standing, Emeritus Member, or Honorary Member, endorse the content of this abstract, for which the above-named Associate Member is sponsor and presenter. (See regulations applying to Associate Members on Page 5.)**  
(Please Print)  
Name  
Signature  
Member No.

**5. Eligibility for Annual Meeting Awards (American and International)**  
- □ A. The PRESENTER of this abstract is a medical or graduate student, physician in training, or postdoctoral fellow.  
- □ B. The PRESENTER meets the criteria in Box A above and is also a minority scientist as defined by the National Cancer Institute (see Page 7).  
- □ C. The PRESENTER of this abstract is a full-time faculty member at a Historically Black College or University (HBCU).

**6. Abstract is to be PRESENTED by:**  
**Member No.**  
(If an AACR Member.)  
Name  
(Please Print)  
Address  
City, State  
Zip/Postal Code  
Telephone No.  
E-Mail Address

**7. As the PRESENTER and as an author of this abstract and on behalf of all the authors, I hereby give exclusive permission to the American Association for Cancer Research, Inc. to record my presentation at the 1999 Annual Meeting and to collect all revenue from subsequent audiocassette sales. I also acknowledge that I am enclosing a completed, signed original and 1 copy of the Copyright Transfer/Conflicts of Interest Disclosure Form.**  
Signature of PRESENTER

**8. Payment of US$40 Abstract Submission Fee.**  
□ Check is enclosed. Please list name of PRESENTER on the check.  
□ I authorize you to charge my credit card for the abstract submission fee.  
- □ VISA □ MasterCard □ American Express

Card No.  
Expiration Date  
Cardholder Name (PRINT)  
Signature

Please check all the information you have entered for correctness and adherence to AACR submission rules. Infractions of sponsorship regulations will result in the rejection and return of the abstract to the SPONSOR without consideration by the Program Committee. Infractions of format, including forms submitted without the required signatures, will result in a fee of US$40 which will be billed to the SPONSOR.
BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 13,500 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:
1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. subscriptions to the Association’s high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
3. an advance copy of the Program and Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
4. reduced registration rates at annual meetings;
5. priority notice of small, focused meetings in the AACR’s exciting series of Special Conferences in Cancer Research;
6. substantially reduced registration rates for Special Conferences;
7. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
8. receipt of AACR Newsletters and other important announcements;
9. early notification of and reduced rates for participation in the AACR Employment Register;
10. an up-to-date Membership Directory of over 13,500 member researchers in the cancer field;
11. the professional benefits of AACR’s public education activities concerning funding for cancer research and press coverage of the latest research findings;
12. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
13. the facilitation of informal scientific exchange with leading researchers in the cancer field; and
14. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application in AACR Office</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:
1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate’s most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate’s achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. –OR– The nominator may sign the application form where indicated under the heading, "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a secondor who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). –OR– The secondor may sign the application form where indicated under the heading, "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West • Philadelphia, PA 19106-3483
Phone: 215/440-9300 • FAX: 215/440-9412
E-mail: membership@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1999 annual dues for active members are $185, $105 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year’s membership dues are paid in full.

Corresponding members are required to pay dues ($105 in 1999) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year’s dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director
# Application for Active or Corresponding Membership

**NAME OF CANDIDATE:**

<table>
<thead>
<tr>
<th>LAST</th>
<th>FIRST</th>
<th>M.I.</th>
<th>DATE OF BIRTH:</th>
<th>Month / Day / Year</th>
</tr>
</thead>
</table>

**PRESENT POSITION/TITLE:**

**INSTITUTIONAL AFFILIATION:**

**INSTITUTIONAL ADDRESS:**

(City) (State/Province) (Country) (Postal Code)

**TELEPHONE NUMBER:**

**FAX NUMBER:**

**E-MAIL ADDRESS:**

**PRIMARY FIELD OF RESEARCH (Please check only one):**

- [ ] Biochemistry and Biophysics
- [ ] Biostatistics
- [ ] Carcinogenesis
- [ ] Cellular Biology and Genetics
- [ ] Clinical Investigations
- [ ] Endocrinology
- [ ] Epidemiology
- [ ] Immunology
- [ ] Molecular Biology and Genetics
- [ ] Other: (Please specify)
- [ ] Virology
- [ ] Experimental Therapeutics

**ACADEMIC DEGREES (Including where and when granted):**

**EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first):**

**PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded):**

**CANDIDATE IS APPLYING FOR (Check one):**

- [ ] Active Membership
- [ ] Corresponding Membership

**CANDIDATE NOMINATED BY*:**

(please print)

**CANDIDATE SECONDED BY*:**

(please print)

**STATEMENT OF SUPPORT**

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

I acknowledge by signing this statement of support, that this candidate adheres to accepted ethical scientific standards and has or will make a long-term contribution to cancer research.

**Signature of Nominator:**

**Date:**

**Signature of Seconder:**

**Date:**

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be Active, Corresponding, Emeritus, or Honorary members of the AACR in good standing.

(This form may be reproduced.)
AMERICAN ASSOCIATION FOR CANCER RESEARCH

Guidelines for Application for Associate Membership

QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and trainings and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege);
2. optional subscriptions to the Association’s high-quality journals: Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates; beginning in 1998 associate members will be able to purchase AACR journals for half the price of a regular member subscription;
3. the privilege of registering for the annual meeting at the low associate member rate;
4. the privilege of electing an Associate Member Council that organizes programs benefitting associate members and that presents their concerns to the AACR Board of Directors;
5. the opportunity to stand for election to the Associate Member Council;
6. preferred access to the AACR Employment Register;
7. priority notification of events in the AACR’s series of special conferences on timely subjects in the field;
8. substantially reduced registration rates at special conferences;
9. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;
10. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
11. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. In addition, the candidate should submit one copy of his or her curriculum vitae. The application may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year’s dues payment must accompany the application. Dues for 1998 and 1999 are $55 for associate members residing in the Americas and $65 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
Fax: 215/440-9412
Email: membership@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1998 and 1999 have been set at $55 per year for residents of the Americas and $65 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1998 for the forthcoming annual meeting must have paid dues for 1998. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member’s registrar, dean, or department head, verifying the member’s current academic status. The Association’s By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1999 may retain associate membership until December 31, 2003. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director

21
# Application for Associate Membership

## NAME OF CANDIDATE: 

<table>
<thead>
<tr>
<th>LAST</th>
<th>FIRST</th>
<th>M</th>
<th>Month / Day / Year</th>
</tr>
</thead>
</table>

---

## INSTITUTIONAL AFFILIATION:

---

## INSTITUTIONAL ADDRESS:

---

## TELEPHONE NUMBER:  

(If outside the United States list country and city codes.)

<table>
<thead>
<tr>
<th>(City)</th>
<th>(State/Province)</th>
<th>(Country)</th>
<th>(Postal Code)</th>
</tr>
</thead>
</table>

---

## FAX NUMBER:

---

## E-MAIL ADDRESS:

---

## PRESENT ACADEMIC STATUS/TITLE (Please check only one):

### Graduate Student  

---

### Medical Student  

---

### Physician in Training  

---

### Postdoctoral Fellow  

---

---

## PRIMARY FIELD OF RESEARCH (Please check only one):

### Biochemistry and Biophysics  

---

### Biostatistics  

---

### Carcinogenesis  

---

### Cellular Biology and Genetics  

---

### Clinical Investigations  

---

### Endocrinology  

---

### Epidemiology  

---

### Immunology  

---

### Molecular Biology and Genetics  

---

### Other:  

---

### (Please specify)  

---

## ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

---

## RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

---

## PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

---

## CANDIDATE NOMINATED BY*:

---

## SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: 

Date: 

I recommend this candidate for Associate Membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: 

Date: 

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. In addition, submit one copy of your curriculum vitae. Envelope a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year’s dues. For 1998 and 1999 dues are $55 for Associate Members residing in the Americas and $65 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

- [ ] current calendar year
- [ ] forthcoming calendar year

(Note: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March or April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

* Nominator must be Active, Corresponding, Emeritus, or Honorary member of the AACR in good standing.
Hotel Reservations

Reserve Early!  Deadline – March 12, 1999

GENERAL INFORMATION

The AACR Housing Bureau will handle all housing needs for the Philadelphia meeting. Participating hotels will not honor direct reservations, and published room rates apply only to rooms reserved through the AACR Housing Bureau.

LIST OF HOTELS

All hotels holding rooms for AACR Annual Meeting attendees are described on the following pages. Please see the hotel map which shows the locations of the hotels being used in Center City Philadelphia.

Hotels at the Philadelphia Airport are approximately 15-20 minutes by bus from the Pennsylvania Conventions Center.

Hotels on City Line Avenue (Adam’s Mark and Holiday Inn City Line) are approximately 20-30 minutes by bus from the Pennsylvania Convention Center.

AACR will provide frequent complimentary shuttle bus service between airport hotels and the Convention Center, between City Line Avenue hotels and the Convention Center, and between Center City hotels (except the adjacent Marriott) and the Convention Center.

HOTEL DEPOSIT

A $150.00 deposit is required in order to reserve a room. The deposit may be made by credit card or check. YOUR CREDIT CARD WILL BE CHARGED IMMEDIATELY. Acceptable credit cards are American Express, Visa, MasterCard, Eurocard, and Discover. Make checks payable to WRI/AACR Housing Bureau.

HOTEL CHANGES AND CANCELLATIONS

If you are unable to attend the Annual Meeting, please cancel your reservation as soon as possible to allow the room to be reserved by another attendee. All changes and cancellations must be made by contacting the AACR Housing Bureau. For a refund of the deposit, the reservation must be cancelled according to the hotel’s cancellation policy which is, in most cases, 72 hours prior to scheduled arrival. Please verify the hotel’s cancellation policy on the reservation confirmation to make sure that no special conditions apply.

FOUR EASY WAYS TO RESERVE HOTEL ACCOMMODATIONS

WEB Reserve a room by visiting the AACR website at www.aacr.org. Attendees who reserve rooms over the Internet will receive an e-mail confirming transmission and a room confirmation by mail. Also visit the website to print an AACR Official Housing Form.

FAX Complete the AACR Official Housing Form enclosed in this booklet and fax to:
1-972-349-7715 (U.S. and International)

PHONE Have the completed AACR Official Housing Form and a credit card ready before calling:
Toll Free (U.S. only): 1-888-447-2319
International: 1-972-349-7409

Hours of operation are 8:00 a.m. – 6:00 p.m. (Central Standard Time)

MAIL Complete the AACR Official Housing Form enclosed in this booklet and return it with credit card information or a check made payable to WRI/AACR to:
AACR Housing Bureau
P.O. Box 864906
Plano, TX 75086-4906
One form per room

If more than one form is needed, this form may be duplicated or printed off the internet (www.aacr.org).

- New Reservation
- Change
- Cancellation

<table>
<thead>
<tr>
<th>FAMILY NAME</th>
<th>FIRST NAME</th>
<th>MI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ADDRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CITY</th>
<th>STATE</th>
<th>POSTAL CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If none of your hotels are available, which is most important?

- LOCATION
- PRICE
- TYPE OF HOTEL

<table>
<thead>
<tr>
<th>HOTEL PREFERENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Map #</td>
</tr>
<tr>
<td>1.</td>
</tr>
<tr>
<td>2.</td>
</tr>
<tr>
<td>3.</td>
</tr>
<tr>
<td>4.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ARRIVAL DATE: April</th>
<th>DEPARTURE DATE: April</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ROOM TYPE</th>
<th>(Check One)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SINGLE</td>
<td></td>
</tr>
<tr>
<td>DOUBLE</td>
<td></td>
</tr>
<tr>
<td>DOUBLEx2</td>
<td></td>
</tr>
<tr>
<td>TRIPLE</td>
<td></td>
</tr>
<tr>
<td>QUAD</td>
<td></td>
</tr>
<tr>
<td>SUITE</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of persons</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

List names of people you are sharing a room with:
(First & Last Name)

- FAX form to: 1-972-349-7715
- OR- MAIL form to: AACR Housing Bureau
  P.O. Box 864906
  Plano, TX 75086-4906

Reservations can also be made by visiting the AACR website
(www.aacr.org) or by calling toll free 1-888-447-2319 (in the U.S.) or
1-972-349-7409 (international) from 7:00am – 7:00pm, CST.
## HOTELS IN PHILADELPHIA, PENNSYLVANIA RESERVING ROOMS FOR AACR REGISTRANTS

<table>
<thead>
<tr>
<th>Map Number</th>
<th>Hotel Name</th>
<th>Special Accommodations</th>
<th>Single</th>
<th>Double</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Philadelphia Marriott (Headquarters Hotel)</td>
<td></td>
<td>$189</td>
<td>$209</td>
</tr>
<tr>
<td>2</td>
<td>Adam's Mark</td>
<td></td>
<td>$196</td>
<td>$212</td>
</tr>
<tr>
<td>3</td>
<td>Airport Hilton</td>
<td></td>
<td>$126</td>
<td>$126</td>
</tr>
<tr>
<td>4</td>
<td>Airport Marriott</td>
<td></td>
<td>$165</td>
<td>$165</td>
</tr>
<tr>
<td>5</td>
<td>Best Western Center City</td>
<td></td>
<td>$89</td>
<td>$99</td>
</tr>
<tr>
<td>6</td>
<td>Best Western Independence Park</td>
<td></td>
<td>$115</td>
<td>$125</td>
</tr>
<tr>
<td>7</td>
<td>Clarion Suites</td>
<td></td>
<td>$129</td>
<td>$139</td>
</tr>
<tr>
<td>8</td>
<td>Comfort Inn Downtown</td>
<td></td>
<td>$109</td>
<td>$119</td>
</tr>
<tr>
<td>9</td>
<td>Crowne Plaza Center City</td>
<td></td>
<td>$149</td>
<td>$163</td>
</tr>
<tr>
<td>10</td>
<td>Doubletree Hotel</td>
<td></td>
<td>$169</td>
<td>$189</td>
</tr>
<tr>
<td>11</td>
<td>Embassy Suites Center City</td>
<td></td>
<td>$152</td>
<td>$152</td>
</tr>
<tr>
<td>12</td>
<td>Embassy Suites Airport</td>
<td></td>
<td>$129</td>
<td>$129</td>
</tr>
<tr>
<td>13</td>
<td>Four Points Sheraton</td>
<td></td>
<td>$99</td>
<td>$99</td>
</tr>
<tr>
<td>14</td>
<td>Four Seasons</td>
<td></td>
<td>$237</td>
<td>$237</td>
</tr>
<tr>
<td>15</td>
<td>Hawthorn Suites</td>
<td>Studio, 1-br suite</td>
<td>$119</td>
<td>$129</td>
</tr>
<tr>
<td>16</td>
<td>Holiday Inn Airport</td>
<td></td>
<td>$110</td>
<td>$110</td>
</tr>
<tr>
<td>17</td>
<td>Holiday Inn City Line</td>
<td></td>
<td>$119</td>
<td>$119</td>
</tr>
<tr>
<td>18</td>
<td>Holiday Inn Express</td>
<td></td>
<td>$110</td>
<td>$115</td>
</tr>
<tr>
<td>19</td>
<td>Holiday Inn Independence Mall</td>
<td></td>
<td>$134</td>
<td>$144</td>
</tr>
<tr>
<td>20</td>
<td>Holiday Inn Stadium</td>
<td></td>
<td>$129</td>
<td>$129</td>
</tr>
<tr>
<td>21</td>
<td>Korman Suites</td>
<td>Studio</td>
<td>$135</td>
<td>$155</td>
</tr>
<tr>
<td>22</td>
<td>Latham</td>
<td></td>
<td>$145</td>
<td>$165</td>
</tr>
<tr>
<td>23</td>
<td>Omni Independence Park</td>
<td></td>
<td>$199</td>
<td>$219</td>
</tr>
<tr>
<td>24</td>
<td>Park Hyatt Philadelphia at the Bellevue</td>
<td></td>
<td>$180</td>
<td>$180</td>
</tr>
<tr>
<td>25</td>
<td>Radisson Airport</td>
<td></td>
<td>$155</td>
<td>$155</td>
</tr>
<tr>
<td>26</td>
<td>Ritz Carlton</td>
<td></td>
<td>$182</td>
<td>$182</td>
</tr>
<tr>
<td>27</td>
<td>Sheraton Society Hill</td>
<td></td>
<td>$177</td>
<td>$197</td>
</tr>
<tr>
<td>28</td>
<td>Sheraton University City</td>
<td></td>
<td>$134</td>
<td>$134</td>
</tr>
<tr>
<td>29</td>
<td>The Warwick</td>
<td></td>
<td>$146</td>
<td>$156</td>
</tr>
<tr>
<td>30</td>
<td>Westin Suites Airport</td>
<td></td>
<td>$129</td>
<td>$129</td>
</tr>
<tr>
<td>31</td>
<td>Windsor</td>
<td></td>
<td>$125</td>
<td>$125</td>
</tr>
<tr>
<td>32</td>
<td>Wyndham Franklin Plaza</td>
<td></td>
<td>$169</td>
<td>$189</td>
</tr>
</tbody>
</table>

Triple and Quad Rates are Available Upon Request.
All Rates Are Subject to State and Local Taxes Totaling 13%.
**HOTEL DESCRIPTIONS (Descriptions Provided by Individual Hotels)**

1. **PHILADELPHIA MARRIOTT (Headquarters Hotel)**  
The Marriott is connected directly to the Pennsylvania Convention Center and is next to the Gallery Mall. This hotel, standing in the hub of the business and historic districts, has three restaurants offering menus for any guest’s taste. Twenty-four hour room service is also available. Facilities include an indoor lap pool, exercise room, aerobics room, whirlpool, and sauna. The Philadelphia Marriott is only eight miles from Philadelphia International Airport and is easily accessible to major interstates and the train station. Guest rooms have upgraded amenities, and health-club facilities, including cardiovascular equipment, are available.  
Rates:  
- Single $189  
- Double $209

2. **ADAM’S MARK**  
The Adam’s Mark is minutes away from historic Philadelphia, the Philadelphia Art Museum, and the Franklin Institute. Famous restaurants include the Marker and Appleby’s, the Player’s Sports Bar and the popular nightclub Quincy’s/Philadelphia. Indoor/outdoor pools, a well-equipped health club, and free parking are available. Convenient to the Pennsylvania Turnpike, Amtrak’s 30th Street Station, and Philadelphia International Airport.  
Rates:  
- Single $196  
- Double $212

3. **AIRPORT HILTON**  
The Airport Hilton Features 331 guest rooms with large desks, climate control, cable TV, HBO, and complimentary newspaper. Guest can enjoy an indoor pool, whirlpool, and health club. Located across from the Philadelphia International Airport, the Hilton provides complimentary airport shuttle and free parking.  
Rates:  
- Single/Double $126

4. **AIRPORT MARRIOTT**  
The Airport Marriott opened its doors in 1995. Conveniently located off I-95 and the High Speed Rail Line, the hotel features a unique skybridge connecting the hotel to the Philadelphia International Airport. Additional hotel amenities include the Riverbend Bar and Grill, Concierge Lounge, an indoor lap pool, and an exercise room.  
Rates:  
- Single/Double $165

5. **BEST WESTERN CENTER CITY**  
From our doors you can walk to the Philadelphia Museum of Art, the Rodin Museum, the Franklin Institute Science Museum, and the Academy of Natural Sciences. We are just minutes from the Pennsylvania Convention Center, the Liberty Bell, Philadelphia Zoo and many of Philadelphia’s finest restaurants. Outdoor pool, fitness center, and free parking are available.  
Rates:  
- Single $89  
- Double $99

6. **BEST WESTERN INDEPENDENCE PARK**  
Philadelphia’s great little hotel, set in the heart of “America’s most historic square mile,” the Best Western Independence Park is centrally located near Penn’s Landing, the Liberty Bell, Franklin Court, Society Hill, and Independence Mall and housed in a historically certified Victorian building. Complimentary European breakfast is served daily.  
Rates:  
- Single $115  
- Double $125

7. **CLARION SUITES**  
This historically registered hotel is located one-half block from the Pennsylvania Convention Center and the Gallery shopping mall, and six blocks from all historical attractions. Large suites feature a dining area, full kitchen, two televisions, and more. The hotel features an intimate lobby lounge, a cafe, and a fitness room. Free deluxe continental breakfast daily.  
Rates:  
- Single $129  
- Double $139

8. **COMFORT INN DOWNTOWN**  
The Comfort Inn features many rooms with waterfront and city views, complimentary deluxe continental breakfast, on-site parking, and courtesy van service to area restaurants, attractions, hospitals, and the Pennsylvania Convention Center. The hotel is within walking distance to the Liberty Bell, Betsy Ross House, Independence Mall, Independence Seaport Museum, and Penn’s Landing Park, and a ferry ride away from the New Jersey State Aquarium at Camden.  
Rates:  
- Single $109  
- Double $119

9. **CROWN PLAZA CENTER CITY**  
The Crowne Plaza offers a central location in the heart of one of the largest commercial, cultural, and historical centers in the country. The Pennsylvania Convention Center is only six blocks away. The hotel features the Elephant & Castle Pub & Restaurant serving breakfast, lunch, dinner and late-night snacks, along with a lobby espresso bar, The E&C Express.  
Rates:  
- Single $149  
- Double $163

10. **DOUBLETREE HOTEL**  
The Doubltree is within walking distance of the Pennsylvania Convention Center, just one mile from Amtrak’s 30th Street Station and 20 minutes from the Philadelphia International Airport. Spacious guest rooms with a panoramic view of the city are across the street from the Academy of Music, the Merriam Theater, and adjacent to the Wilma Theater. The health club features an indoor swimming pool, two racquetball courts, a roof garden with a jogging track, whirlpool, saunas, and steam rooms.  
Rates:  
- Single $169  
- Double $189

11. **EMBASSY SUITES CENTER CITY**  
The Embassy Suites Center City is located on Logan Square in the heart of the city’s cultural center and within walking distance to all of Center City and the Pennsylvania Convention Center. All suites have a living room, kitchen area with refrigerator, wet bar, microwave, and coffee makers, and a separate bedroom with television. Free breakfast buffet each morning and beverages at the manager’s reception each evening. The hotel also has a 24-hour fitness room and sauna.  
Rates:  
- Single/Double $152

12. **EMBASSY SUITES AIRPORT**  
This all-suite hotel is conveniently located one mile from the Philadelphia International Airport. Complimentary breakfast and a two-hour manager’s reception are included with every stay. Indoor pool and workout room are available. Complimentary shuttle service to and from the airport.  
Rates:  
- Single/Double $129

13. **FOUR POINTS SHERATON**  
At the Four Points Sheraton, you can take a swim in our outdoor pool or head outside for some exercise on our jogging trail. For dining, there’s the trendy Newsstand Café, open for breakfast, lunch, or dinner. Located adjacent to Philadelphia International Airport, the Four Points Hotel is just minutes from Center City Philadelphia. Complimentary airport shuttle is also available.  
Rates:  
- Single/Double $99

14. **FOUR SEASONS**  
The proximity to the city’s premier cultural attractions and the Pennsylvania Convention Center makes the Four Seasons Hotel an ideal location. Features include a full-service spa/health club, indoor pool, the Fountain Restaurant, one of the nation’s most acclaimed restaurants, exquisite Sunday brunch, and the Swan Lounge Viennese dessert buffet. Live music Thursday through Saturday.  
Rates:  
- Single/Double $237

15. **HAWKSTON SUITES**  
The Hawthorn Suites Hotel is located directly adjacent to the Pennsylvania Convention Center at 11th and Vine Streets. This all-suite hotel offers spacious studio and one-bedroom suites. All units have efficiency kitchens that feature a microwave, refrigerator, wet bar area, and coffee maker. Included in the group rate is a daily complimentary full breakfast buffet and social hour Monday through Thursday. Other features and amenities include: dual phone lines, complimentary laptop hookup, exercise room, on-site convenience store, free HBO, free daily newspaper, free local phone calls, and valet parking.  
Rates:  
- Single/Double $119  
- 1-br suite $129

16. **HOLIDAY INN AIRPORT**  
The Holiday Inn Philadelphia International Airport is located 3 miles south of Philadelphia International Airport. The hotel features an executive floor, seasonal pool, health facility, and complimentary 24-hour airport transfer. Landings Bar and Grille serves breakfast, lunch, and dinner, and Room Service is available until 11PM. Each room includes a hair dryer, coffee maker, iron, and ironing board.  
Rates:  
- Single/Double $110

27
17. HOLIDAY INN CITY LINE
The Holiday Inn City Line is located in a lovely suburban-like location just northwest of Center City Philadelphia. What makes this location nice is that City Avenue divides Philadelphia from its affluent surrounding neighborhoods and distinguished universities. Free parking, indoor/outdoor pool, and more.
Rates: Single/Double $119

18. HOLIDAY INN EXPRESS
The Holiday Inn Express offers a free deluxe breakfast bar and complimentary local phone calls. The midtown location is within walking distance from historic and cultural attractions, shopping, and the Pennsylvania Convention Center. Easy access to Philadelphia International Airport, Amtrak's 30th Street Station, Sports Complex, and all major highways. Other amenities include self-parking, valet parking, and free access to Bally's Total Fitness Center.
Rates: Single $110 Double $115

19. HOLIDAY INN INDEPENDENCE MALL
The Holiday Inn Independence Mall is located in the heart of the nation's "most historic square mile," within two blocks are Independence Mall, the Liberty Bell, the Betsy Ross House, Franklin Court and the U.S. Mint. Also, it is just three blocks from Penn's Landing and waterfront events. Holiday Inn Independence Mall offers beautifully appointed rooms, the convenience of two restaurants, a lounge, room service, and a gift shop.
Rates: Single $134 Double $144

20. HOLIDAY INN STADIUM
The Holiday Inn Stadium is conveniently located just ten minutes away from the Philadelphia International Airport and only five minutes to Philadelphia's Business and Historic districts. Our amenities include hair dryers and ironing boards in each room. We offer breakfast, lunch, and dinner at our beautiful full service restaurant "Jaws", and spirited libations, your favorite sandwich, and favorite sporting event at our sports bar "Philly Legends." Plenty of complimentary parking is available to all our guests.
Rates: Single/Double $129

21. KORMAN SUITES
This unique hotel has spacious guest suites in the heart of Philadelphia's museum/cultural district and is within walking distance to nightlife and all of Center City. Each room features a microwave, coffee maker, and refrigerator. Spectacular city views, a full-service fitness center, complimentary covered parking, and complimentary shuttle service are available. Also featured is The Grill at Catalina, which offers outstanding Italian cuisine.
Rates: Studio $135 Double $155

22. LATHAM
Located in the heart of Center City, this European-style boutique hotel is known for its intimate, understated elegance and personalized service. Added amenities include nightly turn-down service, imported chocolates, HBO, CNN, ESPN, and in-room movies. Complimentary health-club facilities are available.
Rates: Single $145 Double $165

23. OMNI INDEPENDENCE PARK
This luxury hotel is located in the heart of Independence National Historic Park. All rooms have a dramatic view of the park, minibar, and two phones with computer/fax capabilities. The Omni is within walking distance to Independence Mall, the Liberty Bell, Penn's Landing and trendy South Street. The critically acclaimed Azalea Restaurant invites you to experience award-winning creative regional cuisine.
Rates: Single $199 Double $219

24. PARK HYATT PHILADELPHIA AT THE BELLEVUE
This intimate four-star, four-diamond hotel features French Renaissance architecture crowning the top floors of the restored Bellevue Building. Luxurious guest rooms and suites feature 14-foot ceilings, American Empire-style furnishings, marble baths, and 24-hour room service, as well as a European-style concierge and turn-down service. Enjoy the award winning Founders Dining Room or English afternoon tea. Spa/salon, fitness club, retail shops, food court, offices, and parking garage are also housed within the complex. The hotel is located downtown on the Avenue of the Arts in the heart of the city's theater and cultural district.
Rates: Single/Double $180

25. RADISSON AIRPORT
The Radisson is conveniently located only one mile from the Philadelphia International Airport and easily accessible via Interstates 95, 76 and Routes 291 & 476. A health/fitness area with indoor swimming pool, whirlpool, and exercise equipment are featured in the hotel. The Chesapeake Grille Restaurant offers delicious meals from breakfast through dinner in a contemporary setting. The Atrium Lobby Lounge features a delightful piano bar, Monday through Friday. Trophies sports bar has a 60's flair with entertainment seven days a week.
Rates: Single/Double $155

26. RITZ CARLTON
This AAA Five Diamond property is ranked in the top 20 U.S. hotels by Conde Nast Traveler and Zagat. The hotel is convenient to Philadelphia's business, retail, cultural, and family-oriented attractions. It offers 24-hour room service, fitness center, massage services and valet parking. The Club level features key-only access and a private lounge and concierge. The Dining Room, The Grill, and The Lobby Lounge are noted for outstanding service and cuisine.
Rates: Single/Double $182

27. SHERATON SOCIETY HILL
The newly renovated Sheraton Society Hill is located in the heart of "America's most historic square mile." Guests can enjoy complimentary use of the health club complete with pool, sauna, and top-of-the-line exercise equipment. ladley's Bistro American is open seven days a week for breakfast, lunch, and dinner. The atrium courtyard serves daily continental breakfast, lunch, and cocktails. The Wooden Nickel Pub is also open nightly.
Rates: Single $177 Double $197

28. SHERATON UNIVERSITY CITY
Adjacent to the University of Pennsylvania and Drexel University, this hotel has covered parking, restaurant, deli, lounge, room service, gift shop, and remote TV with Showtime, ESPN, and CNN. The Club floor offers complimentary continental breakfast and afternoon hors d'oeuvres.
Rates: Single/Double $134

29. THE WARWICK
The Warwick, Philadelphia's luxury boutique hotel, boasts a premier location for entertainment and business. Nearby are many fine shops, highly acclaimed restaurants, theaters, museums, and galleries. Enjoy casual but elegant dining in Mia's Restaurant and Mezzano Bar, formal dining in the Prime Rib, or visit Capriccio's Coffee Shop for cappuccino and pastries.
Rates: Single $146 Double $156

30. WESTIN SUITES AIRPORT
The Westin Suites is located just 5 minutes from the Philadelphia International Airport and 15 minutes from the Philadelphia Convention Center. We offer complimentary parking and a free shuttle to and from the airport. This all-suite atrium style hotel offers a newly renovated health facility with an indoor and outdoor pool, jacuzzi, sauna, steam room, and exercise room. We also feature a choice of restaurants and a lounge that features world class cocktails and micro brews. We even have an Express Car Rental desk for your convenience. The Westin Suites is not only all-suite, but all-service.
Rates: Single/Double $129

31. WINDSOR
The Windsor is located at 17th and the Parkway. The Windsor commands a spectacular view of the fountain and museums for which Philadelphia is famous. The hotel is surrounded by legendary cultural and historic attractions, and Philadelphia's greatest concentration of fine restaurants, specialty stores, and night spots. The hotel features a rooftop swimming pool, fitness center, panoramic balcony views, complimentary continental breakfast, valet dry cleaners, full service beauty salon, cable TV, on-site restaurant, concierge, and instant phone service.
Rates: Single/Double $125

32. WYNDHAM FRANKLIN PLAZA
Amid historical and cultural sites, just steps away from the Ben Franklin Parkway museums and the Pennsylvania Convention Center, the hotel is adjacent to I-676 with easy access to I-95 and the New Jersey Turnpike. Facilities include indoor pool, sauna, and whirlpool at the private health club. Underground parking is available.
Rates: Single $169 Double $189
AMERICAN ASSOCIATION FOR CANCER RESEARCH

1999 AACR YOUNG INVESTIGATOR AWARDS

To Support Attendance at the AACR Annual Meeting

AACR Young Investigator Awards support the attendance of medical and graduate students, physicians-in-training, and postdoctoral fellows at the AACR Annual Meeting. Awards are presented to young scientists who are presenters of abstracts that have been highly rated by the AACR Annual Meeting Program Committee. Deadline for submission of abstracts is **November 6, 1998**. Federal government employees are eligible for AACR Young Investigator Awards, but employees of private industry are not. AACR Young Investigator Awards are generously sponsored by: Amgen, Inc., AACR, Bristol-Myers Squibb Oncology, Genetics Institute, Pharmacia & Upjohn, Inc., PharMingen, among others.

Special eligibility restrictions or application procedures apply to the following Young Investigator Awards:

**AACR Gerald B. Grindey Memorial Young Investigator Award** honors the research accomplishments of the late Dr. Gerald B. Grindey. The award is presented to a young scientist submitting an abstract in the field of preclinical science. Deadline for submission of abstracts is **November 6, 1998**.

**AACR-AFLAC Scholar Awards** support the travel and subsistence expenses of AACR Associate Members who are presenters of highly rated abstracts at AACR’s Annual Meeting. Candidates must be AACR Associate Members or submit an Associate Member application no later than the abstract submission deadline of **November 6, 1998**. These awards are sponsored by AFLAC, Inc., as part of its support of AACR’s Associate Member program.

**AACR-ITO EN, Ltd. Young Investigator Awards for Asian Scientists** are awarded to young researchers who are presenters of highly rated abstracts and who will be traveling to the Annual Meeting from throughout Asia. Deadline for submission of abstracts is **November 6, 1998**.

**AACR Minority Scholar Awards** support attendance at the Annual Meeting and AACR Special Conferences through the Comprehensive Minority Biomedical Program of the National Cancer Institute (NCI). Young scientists from minority groups considered underrepresented in cancer research by NCI are eligible for these awards, *i.e.*, African Americans, Hispanic Americans, Native Americans, Native Pacific Islanders, and Alaskan Americans. A separate application form is required and can be obtained by contacting the AACR office. The application deadline is **December 4, 1998**.

**Women In Cancer Research Brigid G. Leventhal Scholar Awards** are for young investigators who are presenters of highly rated abstracts at the AACR Annual Meeting. A separate application form is required and can be obtained by contacting the AACR office. The awards are sponsored by Women In Cancer Research, an adjunct organization of AACR. The application deadline is **December 4, 1998**.

American Association For Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9372
E-mail: horst@aacr.org
<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Chairpersons</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCTOBER 14-18, 1998</td>
<td>Gene Regulation and Cancer (10th Anniversary of the AACR Special Conferences)</td>
<td>Chairpersons: Phillip A. Sharp, Cambridge, MA; Jacqueline A. Lees; Cambridge, MA; and Steven L. McKnight, Dallas, TX</td>
<td>The Homestead, Hot Springs, VA</td>
</tr>
<tr>
<td>NOVEMBER 11-15, 1998</td>
<td>Endogenous Sources of Mutations</td>
<td>Chairpersons: Lawrence J. Marnett, Nashville, TN; James A. Swenberg, Chapel Hill, NC; and Tomas Lindahl, Herts, England</td>
<td>Sanibel Harbour Resort and Spa, Ft. Myers, FL</td>
</tr>
<tr>
<td>JANUARY 8-12, 1999</td>
<td>The Steroid Receptor Superfamily</td>
<td>Chairpersons: Michael G. Rosenfeld, La Jolla, CA, and Christopher K. Glass, La Jolla, CA</td>
<td>Renaissance Esmeralda Resort, Indian Wells (Palm Springs), CA</td>
</tr>
</tbody>
</table>
Advance Registration

FREQUENTLY ASKED QUESTIONS

1. What is the deadline for submitting my registration form?

There are multiple deadlines: if you register by December 1 you will pay the low "early bird" registration fee. If you register after December 1 but on or before February 1 you will pay the "advance registration" fee. From February 1 to February 22 you may still register by mail or fax but you must pay the on-site registration fee.

2. What if I don't register by February 22?

Registration forms received in the AACR office after February 22 will not be processed. However, you may register on site at the Pennsylvania Convention Center in Philadelphia. Registration hours will be 9:00 a.m. to 8:00 p.m. on April 10; 6:30 a.m. to 4:00 p.m. on April 11, 12, and 13; and 6:30 a.m. to 2:00 p.m. on April 14.

3. I am a postdoctoral fellow. May I register at the student rate?

No, you must pay the nonmember rate unless you are or become an Associate Member of AACR (see #4 below).

4. I am a predoctoral student, postdoctoral fellow, or physician-in-training, and I want to become an Associate Member and pay the Associate Member registration fee. What must I do?

You may submit an application for Associate Membership either before or with your Annual Meeting Registration Form, but both must be submitted no later than February 15, 1999, as review of the Associate Member application may delay processing of registration. You may register at the Associate Member rate on the assumption that your application will be accepted; if it is not accepted we will notify you, and you will be required to register at the nonmember rate.

5. I am not currently an AACR member but I have applied or will apply for Active or Corresponding Membership by the September 1, 1998, or January 1, 1999, deadlines. Which registration fee applies?

You must pay the nonmember registration fee. However, when you are officially notified of your election to AACR Membership, you may contact the AACR Office and receive a refund of the difference between the member and nonmember fees.

6. What is your refund policy?

Refunds on registration fees will be granted on written request received in the AACR Office by March 26, 1999. Requests received after this date will not be honored. Receipts and badges (if they have been mailed) must be returned to the AACR Office with the refund request. A cancellation fee of $35 will be deducted from all refunds to cover administrative costs. Copies of the Proceedings may not be returned; an additional $45 will be deducted from the refunds of nonmembers to cover the cost of the Proceedings.

7. How do I receive my Annual Meeting Program and Proceedings?

AACR Members. All AACR members in North America whose 1999 dues are fully paid by February 1, 1999, will automatically receive a copy of the Program and Proceedings prior to the Annual Meeting. AACR members overseas who have paid their 1999 dues by February 1, 1999, will also automatically receive a copy of the Program and Proceedings; however, the receipt of these issues prior to the Annual Meeting is not guaranteed.

Members outside North America who wish to ensure that they receive the Program and Proceedings prior to the annual meeting should check the "Optional Overseas Surcharge" box on the registration form; for an additional fee of $25 the Program and Proceedings will be sent via airmail. This service is not available after February 1, 1999. Please note that AACR members who have not paid their 1999 dues will not be sent a Program and Proceedings and will not be allowed to register for the Annual Meeting at the member rate.

Nonmembers. Nonmembers in North America who register by February 1 will receive a Program and Proceedings prior to the Annual Meeting. Nonmembers who are overseas and wish to ensure that they receive the Program and Proceedings prior to the Annual Meeting may check the "Optional Overseas Surcharge" box on the registration form; for an additional fee of $25 the Program and Proceedings will be sent via airmail. This service is not available after February 1, 1999.

Additional copies of the AACR Proceedings are available for sale from the AACR Office. Fax requests to 215-440-7228.

8. Are there special requirements that nonmember predoctoral students must fulfill in order to register at the predoctoral student rate?

In order to register at the predoctoral student rate, students must complete the "Nonmember Predoctoral Student Certification" section of the registration form, which requires a signature of the registrar, dean, or department head confirming status. Predoctoral student registration forms that do not have this section completed will not be processed. Those wishing to register in Philadelphia at the predoctoral student rate must bring a similar statement on official letterhead in order to register on site at the student rate.

Note: If you have registered at any member rate and have not paid your 1999 dues by February 22, 1999, you will receive an invoice for the difference between the registration fee you paid and the appropriate nonmember rate.
AMERICAN ASSOCIATION FOR CANCER RESEARCH 90TH ANNUAL MEETING
Philadelphia, Pennsylvania • April 10-14, 1999

REGISTRATION FORM

Deadlines:
- December 1, 1998 for low "early bird" rates and to ensure receipt of meeting materials by mail in March
- February 1, 1999 for reduced rates and to ensure receipt of meeting materials by mail in March
- February 15, 1999 for application for Associate Membership in order to register at member rate
- February 22, 1999 for all registration by mail or fax (registration forms received after this date will not be accepted)
- March 26, 1999 to cancel registration and receive refund less cancellation fee

1. NAME AND ADDRESS INFORMATION (please print or type)

First Name/Middle Initial
Are you an ACR Member? ☐ Yes ☐ No
Last Name
Membership #
Title/Department
Institution
Street, Building, or Post Office Box
City State or Province Zip/Postal Code Country (if not U.S.)
Telephone Fax

E-Mail

☐ Check this box if you require special accommodations to fully participate in the meeting.
Describe briefly: ____________________________

2. REGISTRATION RATES

<table>
<thead>
<tr>
<th>Status</th>
<th>Received by</th>
<th>December 2</th>
<th>After February 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active/Corresponding Member</td>
<td>$175</td>
<td>$205</td>
<td>$250</td>
</tr>
<tr>
<td>Nonmember</td>
<td>$350</td>
<td>$395</td>
<td>$450</td>
</tr>
<tr>
<td>Emeritus Member</td>
<td>$60</td>
<td>$60</td>
<td>$60</td>
</tr>
<tr>
<td>Associate Member</td>
<td>$95</td>
<td>$105</td>
<td>$125</td>
</tr>
<tr>
<td>Nonmember Predoctoral Student</td>
<td>$125</td>
<td>$135</td>
<td>$155</td>
</tr>
<tr>
<td>(does not include AACR Proceedings)</td>
<td>$170</td>
<td>$180</td>
<td>$200</td>
</tr>
<tr>
<td>Honorary Member</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td>Optional Overseas Surcharge</td>
<td>$25</td>
<td>$25</td>
<td>N.A.</td>
</tr>
</tbody>
</table>

TOTAL ENCLOSED OR CHARGED $ __________ $ __________ $ __________

3. METHOD OF PAYMENT

☐ Check or money order enclosed, payable to American Association for Cancer Research, in U.S. currency, drawn on a U.S. bank.
☐ VISA ☐ MasterCard ☐ American Express ☐ Eurocard

Card Number ______________________ Exp. Date: ______________________
Signature of cardholder ______________________

4. ADDITIONAL REGISTRANT INFORMATION

Primary Field of Research (Please Circle Only One):
1. Biochemistry/Biophysics
2. Carcinogenesis
3. Cellular Biology and Genetics
4. Clinical Investigations
5. Endocrinology/Signal Transduction
6. Epidemiology
7. Experimental Therapeutics
8. Immunology
9. Molecular Biology and Genetics
10. Prevention
11. Radiobiology/Radiation Oncology
12. Virology
13. Other (please specify): ____________________________

ARE YOU THE PRESENTER OF AN ABSTRACT SUBMITTED FOR THE 1999 ANNUAL MEETING? ☐ Yes ☐ No
☐ Check this box if you are a high school or undergraduate student. This information will be used for the organization of a special educational event during the Annual Meeting for students interested in pursuing careers in science.

5. NONMEMBER PREDOCTORAL STUDENT SECTION

This section must be completed if you are a nonmember predoctoral student. Forms without certification will not be processed.

NONMEMBER PREDOCTORAL STUDENT CERTIFICATION
"I certify that the above named student is presently enrolled at this University and working toward a doctoral degree in a field related to cancer research."

SIGNATURE (Registrar, Dean or Dept. Head)

TITLE ____________________________

UNIVERSITY ____________________________

6. RETURN TO:

Annual Meeting Registration
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483

Fax: 215-440-7228

NOTE: THE INFORMATION ON THE REVERSE SIDE OF THIS PAGE IS CONSIDERED PART OF THE REGISTRATION FORM
FORMS WITHOUT PAYMENT WILL NOT BE PROCESSED
CARCINOGENESIS
SUBCOMMITTEES
Biomarkers, Premalignant Lesions, and Risk Assessment
Walter N. Hittelman, Chairperson
William E. Grizzle
Fred F. Kadlubar
Thomas W. Kensler
Additional member to be appointed
Molecular Carcinogenesis:
Metabolism, DNA Lesions, Mutagenesis and DNA Repair
Peter G. Shields, Chairperson
Vilhelm A. Bohr
F. Peter Guengerich
Steven R. Patierno
Additional member to be appointed
Promotion and Progression
Stuart H. Yuspa, Chairperson
Diane F. Birt
Eileen A. Friedman
Adam B. Gluck

EPIDEMIOLOGY
SUBCOMMITTEES
Analytical Epidemiology in Populations
David J. Hunter, Chairperson
Wong Ho Chow
Nubia Muñoz
Julie A. Ross

Molecular and Genetic Epidemiology
Neil E. Caporaso, Chairperson
Christine B. Ambrosone
Kenneth Offit
Margaret R. Spitz

PREVENTION/BASIC SCIENCE AND CLINICAL STUDIES SUBCOMMITTEE
Preclinical Prevention Studies: Markers and Mechanisms
Michael N. Gould, Chairperson
Pamela L. Crowell
Ronald A. Luft
Bandaru Reddy
Gary D. Stoner

Clinical Prevention Studies
Barney S. Kramer, Chairperson
Steven E. Benner
Ernest T. Hawk
Scott M. Lippman
Gordon McVie

CLINICAL RESEARCH SUBCOMMITTEES
Phase I-Ill Clinical Trials
David R. Soppen, Co-Chairperson
James L. Abbruzzese, Co-Chairperson
Daniel F. Hayes
David Khayat
Makoto Ogawa
Raphael E. Pollock
George Wilding

Organ-Site Specific Studies I : Preclinical Research – Tumor Biology/Translational Research
Kathleen R. Cho, Co-Chairperson
Ruth J. Muschel, Co-Chairperson
Candace L. Gladson
Lora Hedrick-Ellenson
William G. Nelson
Chan H. Park
Ramon A. Parsons

Organ-Site Specific Studies II: Preclinical Research – Experimental Therapeutics
Michael John Hawkins, Co-Chairperson
Robert F. O’zol, Co-Chairperson
Robert Clarke
Robert B. Dickson
Herbert M. Pinedo
Nagahiro Saito
Mario Stoz

Clinical Pharmacology/Modality-Based Clinical Research
Rosa C. Donehower, Chairperson
Karen S. H. Anman
George J. Boul
Michael A. Caligiuri
Roy B. Jones
Paul S. Wissel

Molecular Biology/Molecular Oncology in the Clinic
L. Michael Glad, Chairperson
Carlos Gordon-Cardo
Ethan Dmitrovsky
Madeleine Kane
Homer L. Pearce

Supportive Care, Psychosocial Aspects of Cancer, and Survivorship
Jimmie C. Holland, Chairperson
Harvey Jay Cohen
Additional member to be appointed

ENDOCRINOLOGY/ PRECLINICAL AND CLINICAL SUBCOMMITTEES
Molecular and Preclinical Endocrinology: Receptors and Signal Transduction
Reuben Lotan, Co-Chairperson
Neal Rosen, Co-Chairperson
Anton Jeren
Candace S. Johnson

Clinical Endocrinology
Samuel A. Wells, Jr., Chairperson
Kaoru Abe
Ian D. Hay
Barry D. Netkin

IMMUNOLOGY/ PRECLINICAL AND CLINICAL SUBCOMMITTEES
Tumor Immunobiology: Experimental and Preclinical
David Paul Carbone, Co-Chairperson
Dorothy Herlyn, Co-Chairperson
Paulaute S. Gray
Ellen S. Viitetta
Louis M. Weiner
Additional member to be appointed

Clinical Immunology: Biological Therapy
David Ross Parkinson, Co-Chairperson
Randall Kurzrock, Co-Chairperson
Philip J. Browning
Sunil Kumar Chatterjee
Alan N. Houghton

PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS SUBCOMMITTEES
Drug Discovery, Design, Screening, and Delivery Systems
Randall K. Johnson, Co-Chairperson
Roman Perez-Solar, Co-Chairperson
Bruce C. Baguley
Thomas G. Burke
Anna Maria Cassusa
Additional member to be appointed

Mechanisms of Drug Action
William K. Plunkett, Co-Chairperson
Janet A. Houghton, Co-Chairperson
O. Michael Colvin
William S. Dalton
Patrick M. O’Connor

Drug Resistance I: Multidrug Resistance
Susan E. Kane, Chairperson
James M. Groop
Giuseppe Giaccone
William N. Hahn

Drug Resistance II
Igor B. Robinson, Chairperson
Roger G. Deedee
Scott W. Low
Jeffrey A. Moscow

Pharmacology and Preclinical Toxicology
Michael Christian, Chairperson
Matthew M. Ames
Jerry M. Collins
Additional member to be appointed

Therapeutic Agents I: Small Molecule Approaches
Alexander W. Wood, Chairperson
Ivan D. Horak, Co-Chairperson
Carlos Arteaga
Gordon B. Mills
Allen I. Oliff

Therapeutic Agents II: Biologic Approaches
Eugenie S. Kleinerman, Chairperson
Adrian Harris
Paul Sondel
Additional member to be appointed

Experimental Gene Therapy
Esther H. Chang, Chairperson
David T. Curiel
Mien-Chie Hung
Additional member to be appointed

Topoisomerases, Other DNA-Reactive Agents, and Tubulin Agents
Mary Ann Bjornston, Chairperson
Neil W. Gibson
Neil Osheroff
Eric H. Rubin

RADIOBIOLOGY/RADIATION ONCOLOGY SUBCOMMITTEE
Luka Milas, Co-Chairperson
Zvi Y. Fuchs, Co-Chairperson
William H. McBride
Mark W. Dewhirst
H. Rodney Wells
Additional member to be appointed
Visit the AACR Website!

www.aacr.org

Turn to our website to find:

- AACR Scientific Meetings Schedule
- 1998 Annual Meeting Abstracts
- Abstracts of Articles from AACR Journals
- Instructions for Authors
- Information about AACR Research Fellowships and Young Investigator Awards
- The latest AACR Newsletter, and more!

AMERICAN ASSOCIATION FOR CANCER RESEARCH
Guidelines for Submitting Disks
to
American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

MacWrite
Microsoft Word (DOS, Windows, and Macintosh) WordPerfect (DOS, Windows, and Macintosh)

Also acceptable:

Ability Mass 11 SoloWriter
AmiPro MS Windows Write Sprint
A, S-TeX MS Works Stx
Appleworks MS Works WP Mac SunWrite
ArborTeX Multimate Symphony
ArborText Multimate Advantage TEX
ClarisWorks WP Nibia TEX78
CPT 8000 Nisus (to ASCII file) Text EXecutive
CTOS Notewriter
Diablo Obun Total Word
DisplayWrite OfficeWriter Troff
Duet PC Write uTeX
Einstein PFS First Choice Volkswriter
Enable Professional Write VuWriter
EXP Q&A Write Wang OIS
Final Word Quark XPPress Wang WPS
FullWrite RagTime MS Works Wang Writer
GemiWord Plus (to ASCII file) Window Works
IBM Writing Assistant Rich Text Format Windows Write
Interleaf RSG (to ASCII file) WiziWord
LaTeX Signature Wordstar
Latex SLiTEX Wordstar 2000
Leading Edge SmartWhere WriteNow
Lotus Manuscript SmartWrite II Xerox
Lotus Write

Software packages that we are unable to translate:

FrameMaker Ready, Set, Go
PageMaker Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: ____________________________________________
Name of computer used (e.g., IBM/PS2): ______________________________________
Operating system and version (e.g., DOS 3.3): __________________________________
Word processing program and version (e.g., WordPerfect 5.0): ____________________
   [See reverse for acceptable programs.]

Manuscript number: __________________________________________________________
First author: _________________________________________________________________
Corresponding author (if different from first author): ______________________________
Telephone/FAX numbers: ______________________________________________________

This form (both sides) may be reproduced.
Continued

Do Sex Hormones Play a Role in the Etiology of Esophageal Adenocarcinoma? A New Hypothesis Tested in a Population-based Cohort of Prostate Cancer Patients
Jesper Lagergren and Olof Nyrén

DNA Damage in Mononuclear Leukocytes of Farmers Measured Using the Alkaline Comet Assay: Discussion of Critical Parameters and Evaluation of Seasonal Variations in Relation to Pesticide Exposure

DNA Damage in Mononuclear Leukocytes of Farmers Measured Using the Alkaline Comet Assay: Modifications of DNA Damage Levels after a One-Day Field Spraying Period with Selected Pesticides

CYP17 Genotype and Breast Cancer Risk
Ainsley Weston, Ching-fei Pan, Ira J. Bleiweiss, H. Barbara Ksieski, Noah Roy, Nell Maloney, and Mary S. Wolff

Short Communication

Association between CYP17 Polymorphisms and the Development of Breast Cancer
Kathy J. Helzlsouer, Han-Yao Huang, Paul T. Strickland, Sandra Hoffman, Anthony J. Alberg, George W. Comstock, and Douglas A. Bell

Review

Breast and Cervical Cancer Screening Interventions: An Assessment of the Literature
Helen I. Meissner, Nancy Breen, Cathy Coyne, Julie M. Legler, Donald T. Green, and Brenda K. Edwards

AACR Bulletin Board

ASPO Bulletin Board

Instructions for Authors

Call for Abstracts for 1999 AACR Annual Meeting
See pp. 1–33 in back of issue
Abstract Deadline: Nov. 6, 1998
Cancer Epidemiology
Biomarkers
& Prevention

Editorials

Note from the Editor-in-Chief
Frederick P. Li


Environmental Selenium and Cancer: Risk or Protection?
Larry C. Clark and Elizabeth T. Jacobs

False Presumptions and Continued Surprises: How Much Do We Really Know about Nutritional Supplements and Cancer Risk?
Alan R. Kristal and Gaile Moe

Reply
Marco Vinceti, Kenneth J. Rothman, Margherita Bergomi, Nazzarena Borciani, Luigi Serra, and Gianfranco Vivoli

Research Articles

Excess Melanoma Incidence in a Cohort Exposed to High Levels of Environmental Selenium
Marco Vinceti, Kenneth J. Rothman, Margherita Bergomi, Nazzarena Borciani, Luigi Serra, and Gianfranco Vivoli

Reproducibility of Reported Measurements of Sun Exposure in a Case-Control Study
Dallas R. English, Bruce K. Armstrong, and Anne Kricker

Familial Risks in in Situ Cancers from the Family-Cancer Database
Kari Hemminki and Pauli Vahtinen

Association between Coronary Heart Disease and Cancers of the Breast, Prostate, and Colon

Glutathione S-Transferase μ1 and N-Acetyltransferase 2 Genetic Polymorphisms and Exposure to Tobacco Smoke in Nonsmoking and Smoking Lung Cancer Patients and Population Controls
Fredrik Nyberg, Sai-Mei Hou, Kari Hemminki, Bo Lambert, and Göran Pershagen

Reliability of Serum Measurements of Lignans and Isoflavonoid Phytoestrogens over a Two-Year Period
Anne Zeleniuch-Jacquotte, Herman Adlercreutz, Arslan Akhmedkhany, and Paolo Toniolo

Mechanisms by which Vegetable Consumption Reduces Genetic Damage in Humans
Beatrice L. Pool-Zobel, Achim Bub, Ute M. Liegibel, Silvia Treptow-van Lishaut, and Gerhard Rechkenmer

Hypomethylation in Cervical Tissue: Is There a Correlation with Folate Status?
Brenda M. Fowler, Anna R. Giuliani, Chandrika Pyathilake, Magdy Nour, and Kenneth Hatch

Phase I Chemoprevention Study of Piroxicam and α-Difluoromethylornithine

Continued on Inside Back Cover